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ABSTRACT 
Altered T Cell-Mediated Immunity and Infectious Factors in Autism 
by 
Yong Hu, Doctor of Philosophy 
Utah State University, 2000 
Major Professor: Gregory J. Podgorski 
Department of Biology 
Three major questions were addressed in this dissertation: 1) Do immune 
abnormalities associated with autism primarily alter CD4+ T cell-mediated or humoral 
immune responses? 2) Are specific T cell clones expanded in autism? 3) Which, if any, 
infectious agents play a role in autism? 
lll 
CD4+ T cell-mediated (Thl) or humoral (Th2) immune responses can be 
distinguished on the basis of the cytokines expressed. CD4+ T-cells secrete interleukin 
type 2 (IL-2) and interferon-y, whereas a Th2 response is associated with secretion of 
interleukin type 4 (IL-4). mRNA extracted from peripheral blood mononuclear nuclear 
cells (PBMC) showed significantly increased levels of IL-2 and interferon-y expression in 
24 autistic subjects relative to 19 normal controls. IL-4 mRNA was undetectable in the 
same group of autistic subjects. These results indicate that a CD4+ T cell-mediated 
immune response is associated with autism. 
The expression of V-P chain mRNA was used as a marker of particular T cell 
clone expression. The expression of V-P 13 was significantly elevated in the study group 
lV 
of 11 autistic subjects, but not in 9 normal subjects. This suggests that T cell-mediated 
autoimmunity is a factor in the disease. Two types of human leukocyte antigens (HLA) 
alleles, DR4 and DRl, are associated with autism. The association between V-B 13 
expressing T cell clones and autism was shown even more strongly in the subgroup 
expressing HLA DR4 or DRl. This result suggests a link between antigen presentation by 
HLA DR4 or DRl and expansion ofV-B 13 T cell clones. 
The potential involvement of pathogens suspected to trigger autism was 
investigated by examining T cell proliferation responses to peptide epitopes. As a group, 
the 24 autistic subjects did not show a decreased response to peptides derived from 
rubella virus, influenza A virus, herpes simplex virus type 1, cytomegalovirus, and 
Clostridium tetani. Another model of autism postulates that autism is induced by 
pathogens that possess epitopes identical to the hypervariable region 3 (HVR-3) of the 
HLA DR4 or DRl alleles. Two antigens derived from the Escherichia coli dna J protein 
and the Epstein-Barr virus glycoprotein 110 peptides that contain sequences identical to 
the HVR-3 of the DR4 and DRl alleles were examined for their ability to induce T cell 
proliferation in autistic and normal subjects. No effect of the DR4 or DRl alleles on the 
response to these two antigens was detected. Therefore, both types of results do not 
support the model of immune tolerance in autism. However, average T cell proliferative 
activity was significantly lower in the same autistic subjects. This confirms many prior 
reports that reduced T-cell responses may shape susceptibility to autism. 
Further understanding of how immune abnormalities and infectious agents lead to 
autism should guide development of preventive and therapeutic strategies for this disease. 
(152 pages) 
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CHAPTER I 
INTRODUCTION AND PROJECT OUTLINE 
AN OVERVIEW OF AUTISM 
Autism, also called infantile autism or autistic disorder, is a developmental 
disorder of unknown etiology. Clinically, autism is characterized by obvious deficits in 
the ability to interact and communicate. The primary symptoms of autism are poor social 
development and communication, fixed imagination, and a limited scope of activities and 
interests (Gillberg, 1990). Most researchers now believe that autism is a multifactorial 
disorder (Gillberg and Coleman, 1992). 
Autism is found throughout the world regardless of racial, ethnic, or social 
background. In the U.S., it occurs in 0.03-0.05% of the general population (American 
Psychiatric Association, 1994). There is a biased gender ratio in autism with 3-5 times as 
many males diagnosed with the disease (Rutter, 1978). Although autism affects males 
more frequently, symptoms in females are often more severe. Familial studies indicate 
that about 3% of the siblings of autistic subjects are also affected by autism, a 50-fold 
increase over the frequency seen in the general population (Folstein, 1985; Bolton and 
Rutter, 1990). 
Like most developmental disorders, the symptoms of autism are age-sensitive. 
Autism is usually diagnosed when a child is 2 or 3 years of age (Rutter, 1978). During 
infancy, an affected child does not make eye contact, smile, or engage in other forms of 
communication with parents. In rare cases, the diagnosis of autism is made relatively late, 
when problems with social interactions and language development become evident. 
Current behavioral treatments are designed to promote social involvement and 
improve communication skills (American Psychiatric Association, 1994). They usually 
consist of language training and practice, family counseling, and sometimes include the 
use of medication to control such symptoms as self-destructive behaviors, depression, or 
agitation. Even with these measures the majority of autistic individuals are severely 
impaired in adulthood. Only 1 in 50 patients with autism can work or live independently 
(Shaner, 1997). 
CLINICAL FEATURES OF AUTISM 
The diagnosis of autism is based entirely on behavioral traits. Correct diagnosis 
can be a challenge as autism is difficult to distinguish from other developmental disorders 
such as Rett Syndrome and Asperger Syndrome. Rett Syndrome affects only females and 
is apparent at a later age after normal early development (Gillberg and Coleman, 1992). 
Asperger Syndrome presents social deficits similar to those of autism, but affected 
individuals possess normal mental capacity and verbal and nonverbal communication 
skills (Gillberg and Coleman, 1992). 
The standard criteria for diagnosis of autism are given in the Diagnostic and 
Statistical Manual of Mental Disorders of the American Psychiatric Association ( 1994 ). 
According to this manual, the three abnormalities of autism are: 1) dysfunctional social 
interactions and poor use of nonverbal communication; 2) poor use and understanding of 
spoken language; 3) programmed behaviors and limited imagination as manifested by 
rigid play formats and narrow interest scopes. 
Minimal social participation or association is a striking feature of autism. Obvious 
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difficulties are seen using nonverbal communication through eye contact, facial 
expression, body posture, and gestures (Wing, 1980). Many autistic subjects also 
experience heightened sensory stimulation that affects their perceptions of and responses 
to their environment. As a consequence, autistic children react to stimuli in bewildering 
ways. Emotional aspects of the disease, such as unwarranted anger or happiness and fear 
of normally unprovocative stimuli, further inhibit normal social interactions. 
Children with autism often have dramatic problems with verbal and nonverbal 
communication. Errors in pronunciation and grammar coupled with difficulties 
understanding verbal and body language are commonly observed (Bartak et al., 1975). 
Some individuals have the ability to converse, but are impaired in their ability to initiate 
or continue conversations. Rejection of imitative social actions and use of stereotypical 
patterns of language are common characteristics of autism (Gillberg, 1990). These 
communication deficits further isolate autistic children. 
The interests of autistic subjects are limited. Attention often is fixed upon a single 
object. Repetitive body movements and self-stimulating behavioral rituals, such as 
rocking or scratching, also are common manifestations of autism. 
More than 75% of children with autism meet definitions of mental retardation, 
having an Intelligence Quotient (IQ) of< 70 (Lotter, 1966). About 40% of autistic 
children have an IQ of less than 40. Ironically, about 10% of autistic subjects exhibit 
extraordinary ability in one specific skill, such as memorization, mathematical 
calculation, musical expression, or art. Unfortunately, the same autistic child may be 
dysfunctional in other areas, unable to answer such basic questions as what did you eat 
for dinner? Who was yesterday's playmate? 
Occasionally, other medical conditions are associated with autism. These include 
epilepsy (Taft and Cohen, 1971 ), vision and hearing impairments, fragile X syndrome 
(Steffenburg and Gillberg, 1986; Gillberg, 1992), encephalitis, chromosome 
translocation, maternal rubella, and tuberous sclerosis (Lotter, 1974). 
BIOLOGY-BASED VIEWS OF AUTISM 
Views of autism have evolved over the past 50 years from Kanner's early concept 
of autism as an outcome of poor parenting to more recent ideas of autism as a 
multifactorial, biologically based disorder (Gillberg, 1992; Burger and Warren, 1998). A 
synopsis of some of the major ideas of the etiology of autism is presented below. These 
hypotheses are summarized in Figure 1.1. 
Psychogenic Theory 
Kanner (1943), the first investigator to describe autism as a defined 
developmental disorder, believed autism resulted from parenting failure. He erroneously 
thought that autistic children came primarily from upper class families and that parents of 
autistic children failed to provide critical language training, social interactions, and 
physical attachment to their children because of their preoccupation with professional or 
social success. This idea came to be known as the psychogenic theory of autism. 
Experimental evidence for Kanner' s theory came from the pioneering studies of 
Harlow and McKinney (1971 ), who showed that rhesus monkey infants that were isolated 
from parents and all other social contacts developed symptoms resembling human 
infantile autism. Even when these animals were later released from isolation chambers 
and returned to their mothers, most continued to display autism-like symptoms of social 
Parental failure 
Neurological 
abnormalities 
I > 
I > 
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Fig. 1.1. Hypotheses for the etiology of autism. 
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isolation, poor communication, abnormal, repetitive movements, and self-damaging 
behavior. 
Harlow and McKinney ( 1971) proposed that a lack of parental contact and social 
stimulation caused underdevelopment of the brain. They hypothesized that parental touch 
and emotional nourishment are essential to the normal development of the central 
nervous system in infant monkeys and humans. This psychogenic theory of autism 
became widely accepted. 
Later studies revealed serious flaws in the psychogenic theory. A major 
discrepancy between theory and reality was the finding that the autism rates were 
independent of social class, economic status, patterns of feeding, language training, 
general sensory stimulation, and the degree of parental emotional attachment and 
nurturing (DeMyer et al., 1972). 
Genetic Factors in Autism 
A role for genetic factors was suggested by a study of concordance in mono- and 
dizygotic twins (F olstein and Rutter, 1977; F olstein, 1985). The concordance of autism in 
monozygotic twins is about 36%, while the concordance in same-sex dizygotic twins 
approaches zero, arguing strongly for a role of genetic factors in the disease. The fact that 
concordance in monozyogotic twins is not perfect is also significant because it points to 
the existence of environmental factors in disease development. More recently, Warren 
and colleagues indicated that immunogenetic factors play a significant role in the 
development of autism (Warren et al., 1986). Human leukocyte antigen (HLA) DR 
molecules present antigens to T effector cells and are essential for T cell function. 
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Particular HLA DR alleles were found at a much higher frequency in autism, suggesting 
that T cell functions are involved in the etiology of the disorder (Warren et al., 1992, 
1996). 
Dopamine Imbalance 
High levels of the central nervous system (CNS) neurotransmitter dopamine have 
been documented in a significant number of autistic individuals (Minderaa et al., 1989; 
Barthelemy et al., 1989). Dopamine regulates many CNS functions, including memory, 
hormone secretion, emotional status, and alertness. Dopamine levels in autistic 
individuals are elevated because the activity of dopamine hydroxylase, the enzyme that 
degrades dopamine, is reduced in the disease (Goldstein et al., 1976; Lake et al., 1977; 
Cohen et al., 1977). Administration of dopamine analogs in some patients makes autistic 
symptoms more severe, while drugs that lower dopamine have the opposite effect 
(Campbell et al., 1976, 1978). These findings clearly implicate dopamine imbalances in 
some autistic individuals. 
Infectious Factors in Autism 
Infections, especially viral infections, appear to be an important factor in autism. 
Rimland (1964) first found that children infected by rubella virus developed autism. 
Later, similar studies were reported by Desmond et al. (1967), Chess (1971), and 
Freedman et al. (1977). Taken together, these studies indicate a nearly 200-fold increase 
in the frequency of autism in rubella-infected children over that seen in the general 
population (Chess, 1977). Subsequently, other viruses have been implicated in autism 
through case studies. These include cytomegalovirus (CMV) (Stubbs, 1978), herpes 
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simplex virus 1 (HSV-1) (Ritvo et al., 1990), varicella-zoster virus (VZV) (Knobloch 
and Pasaminick, 1975), and human immunodeficiency virus type 1 (HIV-I) (Schmitt et 
al., 1991). Infection by these viruses during either prenatal or postnatal development is 
thought to be possibly involved in autism. 
Immune system abnormalities and viral infections may interact in the etiology of 
autism. In this scenario, viral infections early in life induce B or T cell abnormalities that 
either cause autoimmUPity or allow pathogen persistence. In either event, the 
consequence is CNS damage that may lead to autism. The studies reported in Chapter 2, 
3 and 4 of this dissertation explore aspects of the potential interrelationship between 
infection and immune abnormalities in autism. 
Immune Defects in Autism 
Immune system defects appear to be an important factor in autism. Two broad 
classes of these defects have been investigated intensively during the past two decades: 
immune tolerance induced by early pathogen exposure and autoimmune responses 
directed against the CNS. The investigation of both forms of immune system abnormality 
forms a major part of this dissertation. 
The hypothesis that immune tolerance induced by infection is a factor in autism 
came from the observation that a group of normal and autistic subjects revealed a striking 
difference in the ability to produce antibodies against rubella vaccine. Stubbs (1976) 
found that 6 of 15 of these autistic children did not produce antibodies against rubella 
vaccination challenge whereas all eight normal controls produced antibodies after rubella 
vaccination. Stubbs (1976) proposed that some cases of autism may result from immune 
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tolerance induced by prenatal or early postnatal rubella infection. This immune 
tolerance is postulated to lead either to persistence of the original pathogen or 
susceptibility to secondary infections. Persistent, low-level infection in immune-tolerant 
individuals may result in the CNS damage leading to autism (Stubbs, 1976). 
The existence of CNS autoimmune diseases such as multiple sclerosis (Kennedy 
and Karpus, 1999) and Sydenham's chorea (Moore, 1996) prompted investigations of 
autoimmunity in autism. Autoimmunity directed against at least two CNS components 
has been discovered in autistic patients. Weizman et al. (1982) found T cell-mediated 
immune responses to human myelin basic protein in 13 of 17 autistic patients, but not in 
any of 11 patients suffering from other mental disorders. This report is important because 
it indicated that activated T cells are involved in autism and can target CNS struchlfal 
proteins. Singh et al. (1993) independently found autoantibodies to myelin basic protein 
in children with autism but not in normal controls. Finally, Todd and Ciaranello (1985) 
discovered autoantibodies to CNS serotonin receptors in the cerebrospinal fluid of 7 of 15 
autistic patients and in none of 15 normal controls. These studies provide compelling 
evidence for the existence of autoimmunity in autistic individuals. The fact that activated 
T cells easily cross the blood-brain barrier (Wekerie et al., 1986) strengthens models ofT 
cell-mediated autoimmune damage to the CNS system as a cause of autism. 
Findings that indicated immune abnormalities in autism sparked a series of 
investigations into the cellular basis of these immune defects. These studies have 
uncovered an array ofT cell alterations in autistic subjects. Stubbs et al. (1977) examined 
lymphocyte proliferation stimulated by phytohemagglutin (PHA) as an indicator of T cell 
function. PHA primarily stimulates CD4+ T cells. The lymphocytes of autistic subjects 
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displayed a significantly decreased proliferation response after stimulation with PHA 
(Stubbs, 1976). A similar investigation performed by Warren and his coworkers 
independently confirmed this finding (Warren et al., 1986). 
Warren's group went on to investigate the activity of natural killer (NK) cells in 
autism (Warren et al., 1987). NK cell activity provides non-specific immune protection 
against viral infections and malignancy, and NK cells help to regulate immune responses. 
In many autoimmune disorders, including multiple sclerosis (MS), rheumatoid arthritis 
(RA), and Sjogren's syndrome (Sibbitt and Bankhurst, 1985; Takeda et al., 1987), NK 
cell activity is decreased significantly. Warren et al. (1987) found that NK cell activity 
was reduced in 12 of 31 patients with autism and none of 23 normal individuals. 
Two types of T cells are distinguished on the basis of their expression of the 
CD4+ or CD8+ cell surface marker proteins. CD4+ T cells, also known as helper T cells, 
work against intracellular antigens, and CD8+ T cells, also known as cytotoxic T cells, 
target extracellular antigens. Warren et al. (1986) reported that patients with autism had a 
reduced number of circulating CD4+ T cells, whereas numbers of CD8+ T cells were 
normal. This finding was confirmed by Y onk et al. (1990). 
Activated T cells express surface proteins, called HLA DR molecules, which 
regulate T cell activation and T cell interactions. Warren et al. (1995) found that the DR+ 
marker was expressed in 14 of26 (53%) autistic subjects compared to only 3 of27 (11 %) 
age-matched healthy controls. Additionally, comparisons between age-matched DR+ 
autistic and normal individuals showed an 8-fold increase in the number of DR+ T cells 
in autistic subjects. This indicates that T cell activation occurs in autism and suggests 
involvement of the immune system in the disease. A similar elevation of DR+ markers 
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has been reported in other autoimmune disorders (Effrench-Constant, 1994), including 
the autoimmune disease rheumatoid arthritis (Auger and Roudier, 1997). 
The cytokine expression profiles of patients with autism are unusual and also 
suggestive of immune system dysfunction. Cytokines are major mediators of immune 
responsiveness. Singh and colleagues found elevated levels of interleukin type 2 (IL-2) 
(Singh et al., 1991) and interleukin type 12 (IL-12) and interferon-y (Singh, 1996) in the 
serum of autistic subjects. These results indicated the involvement of a class of helper T 
cells, known as Thl cells. Gupta et al. (1998) also reported imbalances in cytokine levels 
in autistic individuals and increased levels of interleukin type 4 (IL-4) were found which 
is in contrast to the studies of Singh and his associates. These results suggest involvement 
of Th2 helper T cells in autism. Chapter 2 of this dissertation reexamines this issue of a 
role for Thl or Th2 cells in autism using a more sensitive methodology. 
Finally, there is evidence of non-T cell immune abnormalities in autism. In a 
search for abnormal B cell functions, Warren et al. (1997) uncovered lower serum levels 
of imrnunoglobulin A (IgA) in 20% of autistic subjects studied. IgA is the major 
imrnunoglobin secreted in the digestive tract, respiratory system, and milk. Warren and 
colleagues also found decreased levels of circulating complement type 4B (C4B) in some 
autistic patients (Warren et al., 1995). C4B is an important element of the complement 
cascade and its downregulation would reduce the efficiency of antigen destruction. 
THl VS TH2 CYTOKINES AND THEIR 
IMPLICATION IN HUMAN DISEASES 
Blood is a heterogeneous mixture containing red and white blood cells. About 
25% of white blood cells are lymphocytes, key components of the specific immune 
system (Geha et al., 1994). Among lymphocytes, B lymphocytes, or B cells, are 
responsible for humoral immunity, while T lymphocytes, also called T cells, control 
cellular immunity. 
Thl and Th2 Cytokines 
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There are distinct sets of T cells that perform different functions. CD8+ T cells, 
also known as cytotoxic T cells, defend against extracellular microorganisms. Activated 
cytotoxic T cells attack and kill these pathogens directly. CD4+ T cells, also called helper 
T (Th) cells, activate macrophages and B cells. There are two major types of CD4+ T 
cells, Thl and Th2 (Romagnani, 1992, 1995, 1996, 1997). Thl and Th2 cell types, their 
functions, and the cytokines they produce are shown in Figure 1.2. Thl cells pick up cells 
that are infected with granular intracellular antigens. Eventually, macrophages are 
activated by Thl T cells to engulf the infected cell. Th2 cells detect extracellular 
antigens, then activate B cells to produce specific antibodies. Thl and Th2 CD4+ T cells 
produce distinct types of cytokines and these patterns of cytokine production are used 
experimentally to distinguish the T helper cell types (Mosmann and Coffman, 1989; 
Limaye et al., 1990). Thl cells primarily produce interferon-y and interleukin type 2 (IL-
2), whereas Th2 cells secrete IL-4 and IL-5 (Mosmann and Sad, 1996). 
Role of Thl and Th2 Cytokines in Disease 
Helper T cell abnormalities play a role in disease. Activated Thl cells are found 
in affected tissues of disease that include MS (Laman et al., 1998; Windhagen et al., 
1998), RA (Miossec and van den Berg, 1997; Moore, 1999), autoimmune thyroid disease 
(Martin et al., 1990), Crohn's disease (Raedler et al., 1986), and acute allograft rejection 
B cells 
Interferon-y 
secretion 
Macrophage 
CD 
!Mib
\ 
• 
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tivate �--r- IL-2 secretion
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Fig. 1.2. Thl and Th2 types of CD4+ helper T cells. Thl helper T cells activate macrophages and inhibit B cells. 
Th2 helper T cells show the converse pattern, activating B cells and inhibiting macrophages. Activation of each T cell 
type is characterized by secretion of specific cytokines. 
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(De Carli et al., 1994). In animal models, adaptive transfer of activated Thl cells 
induces experimental autoimmune uveoretinitis and insulin-dependent diabetes (reviewed 
by Liblau et al., 1995). Activated Th2 cells are present in tissues affected by progressive 
systemic sclerosis and chronic graft-versus-host rejection (Krenger and Ferrara, 1996). In 
all autoimmune diseases where helper T cells play a dominant role, cytokines in the 
peripheral blood accurately indicate the type of helper T cell that infiltrates affected 
tissues. For example, in animal models of multiple sclerosis, activated Thl cells are 
found in the CNS (Link, 1998) and Th I-specific cytokines are elevated in the peripheral 
blood (Okuda et al., 1998). Furthermore, in rheumatoid arthritis, distinct cytokine 
patterns correlate well with the disease stages (Kanik et al., 1998). 
Abnormal T helper cell activation may be involved in psychiatric disorders. 
Abnormal cytokine levels are detected in the cerebrospinal fluid of children suffering 
from obsessive disorder and schizophrenia (Mittleman et al., 1997). In autism, Singh et 
al. discovered unusually high serum levels ofIL-2 and IL-12 (Singh et al., 1991; Singh 
1996), indicating Thl cell activation. Gupta et al. (1998) also found cytokine elevation in 
autism indicative of helper T cell activation, but saw an increase in IL-4, a marker of Th2 
cell activation. The studies reported in Chapter 2 of this dissertation take an alternative 
experimental approach to reexamine the question of Thl or Th2 cell activation in autism. 
T CELL RECEPTOR REPERTOIRES IN 
HUMAN DISEASES 
The T Cell Receptor (TCR) 
T cell receptors are transmembrane proteins that allow antigen recognition. The 
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predominate TCR is a heterodimer made of a and p chains, although TCRs composed 
of y and<> chains occur at lower frequency. The structure of the ap TCR heterodimer is 
presented in Figure 1.3. Each T cell expresses only a single type of TCR heterodimer and 
as a consequence recognizes a restricted set of antigens presented in the context of major 
histocompatibilty complex (MHC) molecules present on the surface of antigen-presenting 
cells (Geha et al., 1994). Binding of the antigen-MHC complex to the TCR activates or 
inhibits T cell proliferation. Currently, 50 a and 60 p TCR chains are known (Spinella 
and Robertson, 1994; Garcia et al., 1999). These allow formation of a huge number of 
heterodimers that can recognize an even larger number of antigens (Imberti et al., 1993; 
Arden et al., 1995; Vandenbark et al., 1996). Each polypeptide chain is composed of a 
constant and a variable domain. The specificity of T cell-antigen interaction is due 
primarily to the type of p chain that is expressed (Geha et al., 1994). 
The TCR repertoire is determined by many factors, including genetic background. 
Expansion of specific T cell clones is observed in many disease conditions, including T 
cell-mediated autoimmune disorders, during infection (Islam et al., 1996) and stimulation 
by superantigens. Expanded T cell clones are identified on the basis of the T cell 
receptors they express, with the specific type of variable region of the p (V-P) chain 
serving as a marker. Two methods are available for detection of specific V-P chains: flow 
cytometry and reverse transcription-polymerase chain reaction (RT-PCR). RT-PCR has 
the advantages of greater sensitivity and the ability to detect all major specific V -P chains 
TCR, and is now the method of choice. 
Cytoplasm Intracellular region 
Cell membrane 
� 
Transmembrane region 
Disulfide bond Hinge region 
Carbohydrate Constant region 
a chain � chain 
Hypervariable region 
Antigen binding region 
Fig. 1.3. T cell receptor (TCR) structure. 
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Altered TCR Repertoires in Disease 
T cell clone expansion is a hallmark of autoimmune diseases. These documented 
autoimmune diseases include MS (Wucherpfennig and Hafter, 1995; Lozeron et al., 
1998), type I diabetes ( Atlan-Gepner et al., 1997), systemic lupus erythematosus 
(Furukawa et al., 1996; Holbrook et al., 1996; Mato et al., 1997), sarcoidosis (Moller et 
al., 1988), Kawasaki disease (Abe et al., 1993), microscopic polyarteritis (Simpson et al., 
1995), primary biliary cirrhosis, Sjogren' s syndrome, and RA (Jenkins et al., 1993). In 
every one of these disorders, one or a few helper T cell clones form the predominant 
activated T cell population. For example, T helper cells are known to infiltrate affected 
nervous tissue of MS patients and RT-PCR has shown that these cells express V-P 8 
almost exclusively. In RA, similar RT-PCR analysis shows that either V-P 14 or V-P 17 
is expressed by the helper T cells collected from synovial fluid of affected joints. The 
same V-P regions are expressed by the majority of helper T cells in peripheral blood of 
RA patients, indicating a good correlation between expanded T cells populations in 
peripheral blood and affected tissue. MS and RA provide two examples of autoimmune 
diseases in which a specific T cell population is expanded. The studies reported in 
Chapter 3 of this dissertation use RT-PCR of RNA isolated from peripheral blood to learn 
if particular T cell clones are expanded in autism. 
In animal models of autoimmune disorders, there is good evidence that T cell 
clone expansion is a cause rather than a consequence of disease. Transfers of splenic T 
cells from animals with experimentally induced type I diabetes er RA r�sults in the 
development of the corresponding diseases in genetically compatible animals. In murine 
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experimental autoimmune thyroiditis, the unique and causative TCR V-P clones are 
also identified (McMurray et al., 1996). 
The enhanced expression of specific cytokines and T cell clone expansion may be 
related (Parronchi et al., 1991; Olsson et al., 1995). Initial stimulation of T cell clones by 
exposure to antigens will induce specific patterns of cytokine secretion. In turn, these 
cytokines feed back upon the initially stimulated T cell clone in an autocrine feedback 
loop to further stimulate clonal expansion. This clonal expansion fueled by increased 
cytokine expression may lead to autoimmune diseases. This model is supported by 
investigations of MS where it was found that upregulation of Thi cytokine expression 
and T cells clones expressing V-P 8 were interrelated in both MS patients and in animal 
models of the disease (Olsson et al., 1995) 
In addition to serving as a marker, the V-P region expressed by T cell clones 
presents a target for therapy. In animal models of MS, administration of monoclonal 
antibodies against V-P 8 decreased the severity of symptoms (Urban et al., 1988; 
V andenbark et al., 1989; Acha-Orbea et al., 1988). Knowledge of potential T cell clones 
that predominate in autism may offer the hope for similar therapy. 
Susceptibility to most autoimmune diseases involves a significant genetic 
component. An important genetic marker for susceptibility to any autoimmune disease is 
the MHC genotype (Albani et al., 1992; Ikeda et al., 1996), especially alleles of the DR 
locus. This locus encodes DR proteins that are key elements of the MHC that presents 
antigens to T cells (Geha et al., 1994; Tuokko et al., 1998). Particular DR alleles occur at 
high frequency in many autoimmune disorders (Geha et al., 1994; Tuokko et al., 1998). 
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For example, in MS DR2 is commonly present, in rheumatoid arthritis DR4 
predominates, in type I diabetes DR3 and DR4 occur frequently, and in myasthenia 
gravis, DR3 is frequently present. A very high frequency of DR4 or DRl is associated 
with autism (Warren et al., 1995). The reasons behind the association between specific 
DR alleles and autoimmune diseases are unknown, but one hypothesis is that particular 
DR alleles present antigens derived from infectious pathogens in a manner that induces T 
cells to target not only the foreign antigen but self-antigens as well (Ou et al., 1998, 
1999; Williams et al., 1993). This leads to expansion of self-reactive T cell populations 
that destroy host tissue. 
INFECTIOUS AGENTS SUSPECTED 
IN AUTISM 
Epidemiological investigations and case studies both suggest a close link between 
viral infections early in life and autism. These viruses include rubella (Rimland, 1964), 
CMV (Stubbs, 1978), HSV-1 (Ritvo et al., 1990), VZV (Knobloch and Pasaminick, 
1975), mumps (Deykin and Macmahon, 1979), and HIV-I (Schmitt et al., 1991). Rubella 
is the strongest candidate pathogen in autism with other viruses implicated primarily 
through case studies. The evidence for rubella virus, CMV, and HSV-1 as causative 
agents of autism is discussed below. 
Rubella Virus 
After a rubella virus epidemic occurred in New York City, 243 infected children 
were followed in a prospective study. Within this group 10 subjects developed autism 
with full symptoms and 8 subjects with partial symptoms (Rimland, 1964). The infected 
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children were followed, and another 4 subjects were later diagnosed with autism 
(Chess et al., 1978). This is a remarkably high frequency of autism, roughly 175-fold 
greater than that of the general population. In another study of 210 rubella virus-infected 
children, 7% were diagnosed with autism (Stubbs et al., 1977). Small-scale investigations 
in Italy (Elia et al., 1990) and Utah (Ritvo et al., 1990) uncovered the same association 
between childhood rubella virus infection and autism. An important point stemming from 
these studies is that autism may develop either shortly (Freedman et al., 1977) or a 
significant time after acute rubella virus infection (Pfefferbaum, 1996). 
Rubella virus is best known for causing birth defects when infection occurs during 
pregnancy ( congenital rubella syndrome), especially during the first trimester. In 
congenital rubella syndrome, rubella virus particles present in the maternal circulation 
cross the placenta and damage the fetus (Lim et al., 1995; Lane et al., 1996). Rubella 
virus infection also causes encephalitis that leads to cognitive, motor, and behavioral 
deficits that are first seen in early infancy. Rubella-induced encephalitis is long lasting, 
with infectious particles present in blood and cerebrospinal fluid 1 year after birth in 80% 
of congenitally infected infants (Cradock-Watson et al., 1989; Katow, 1998). In vitro 
studies also indicate that rubella virus attaches to human lymphocytes and substantially 
decreases lymphocyte functions (Plotkin et al., 1965). Although the role of rubella 
infections in autism is unknown, both CNS damage and alteration of lymphocytes 
activity are two possibilities. 
CMV 
Congenital CMV infection is a significant health problem in the United States 
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(Starr et al., 1970). The view that CMV infection is a factor in autism comes from a 
series of case studies. Stubbs (1978) reported a case of an autistic patient who suffered 
congenital CMV infection. He speculated that congenital CMV infection could have led to 
the autistic symptoms probably through the same mechanisms that links rubella virus 
infection and autism. In a prospective study of 72 infants congenitally infected by CMV 
and followed for 3 years (Blattner, 1974), three cases of autism developed. In other studies, 
maternal CMV infection during pregnancy was suspected to produce autism. In these cases, 
congenital CMV infection of autistic children born to CMV-infected mothers was indicated 
by the presence of antibodies to CMV, viral particles in urine, hearing loss, and damage to 
the retina that appeared to be the result of CMV infection (Markowitz, 1983; Stubbs et al., 
1984; Ivarsson et al., 1990). 
HSV-1 
The case for HSV-1 in autism comes from case studies showing antibodies 
against HSV-1 in autistic children and their mothers and an association between HSV -!­
induced encephalopathy and autism. Like rubella virus and CMV, neonatal HSV-1 
infection occurs commonly and affects about 5 per 10,000 of newborn infants in the U.S 
(Brown et al., 1991). Delong and his associates were the first to report a possible link 
between congenital HSV-1 infection and autism (Delong et al., 1981 ). In their study, 
three boys with autism were found to have had congenital HSV-1 infection that led to 
encephalopathy. These three individuals were asymptomatic for autism prior to their 
HSY-I-induced encephalopathies. Neurological examinations revealed CNS damage in 
two of these autistic children. In one case, damage to the left temporal lobe was found 
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and a high serum antibody titer for HSV-1 was detected. In another case, autism 
developed in a previously normal child 10 days after developing HSY-induced 
encephalitis (Gillberg, 1986). Bilateral damage in the temporal lobes of the second 
patient, presumably caused by HSV-1 infection, was also detected (Gillberg, 1986). 
Finally, Ritvo et al. (1990) found two cases in which autistic children and their mothers 
had antibodies against HSV-1 and speculated that there may be a causal relationship. 
Vaccination 
An abnormal response to vaccination has been suggested to be an important factor 
in the etiology of autism. There are anecdotal reports of children developing autism 
within months of immunization with measles-mumps-rubella (MMR) or diptheria­
pertussis-tetanus (DPT) vaccines. Munyer et al. (1975) found that long-lasting, depressed 
lymphocyte functions developed in some individuals after MMR vaccination, and Rossier 
et al. ( 1994) reported an absence of cell-mediated immunity to rubella virus in 19 of 25 
normal children 5 years after MMR vaccination. The generally depressed immune 
function seen in autistic patients (Yonk et al., 1990; Warren et al., 1990) and these 
observations of depressed immune functions following vaccination have led to the 
hypothesis that some autistic individuals develop their symptoms as a consequence of 
vaccine-induced immune depression (Campbell, 1989; McFarland, 1999). Possibly the 
decreased immune functions induced in some individuals allow persistent secondary viral 
infections that damage the CNS and lead to autism. 
RESEARCH GOALS 
This dissertation examined three questions related to immune abnormalities in the 
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etiology of autism. The first question was which type of helper T cell, Thl or Th2, is 
involved in the disease. Two previous works showed expansion of helper T cell 
populations in autistic individuals, but came to conflicting conclusions regarding which 
helper T cell type was involved (Gupta et al., 1998; Singh, 1996). The second question 
was whether a particular T cell clone predominates in autistic individuals. This would 
provide further evidence of altered T cell immune functions in autism. The final question 
of this study asked if specific pathogens are involved in autism. 
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ABSTRACT 
CHAPTER2 
CYTOKINE EXPRESSION PATTERNS INDICATE 
A Thl TYPE OFT CELL RESPONSE IN AUTISM 
38 
Abnormal helper T cell function may underlie the pathology of autoimmune 
disorders and some psychiatric diseases of children, including autism. Helper T cells 
activate and inhibit a variety of other effector cells and are classified as Thl or Th2 types 
based on the effector cells they control. Thl cells secrete interleukin type 2 (IL-2), 
interferon-y and interleukin type 12 (IL-12), and Th2 cells secrete interleukin type 4 (IL-
4). Two previous reports have shown that helper T cells are involved in autism, but came 
to conflicting conclusions regarding whether these were Th 1 or Th2 cells. In order to 
clarify which type of helper T cell is associated with autism, we employed competitive 
reverse transcription-based polymerase chain reaction (RT-PCR) to examine the profile 
of cytokines expressed in autistic and normal individuals. The expression of interferon-y, 
IL-2, and IL-4 mRNA was examined in phytohemagglutinin (PHA)-stimulated peripheral 
blood mononuclear cells (PBMC) obtained from 24 autistic subjects and 19 normal 
controls. Levels of interferon-y and IL-2 mRNA were significantly higher (p < 0.05 and p 
< 0.0002, respectively) in the autistic group. IL-4 was detected in only 1 of 24 autistic 
subjects and in 5 of 19 of normal individuals (p < 0.005). These results indicate that 
activated Thl T cells are associated with autism. 
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INTRODUCTION 
Autism, also called infantile autism or autistic disorder, is a major pervasive 
developmental disease with an occurrence of 0.03-0.05% in the general population 
(Shaner, 1997). It is characterized by social isolation, language deficits, and narrow 
activity and interest scopes. The etiology of autism is unknown, and multiple causes have 
been postulated, including genetic factors (Folstein and Rutter, 1977; Folstein 1985), 
neurological dan1age (DeMyer et al., 1972), immune dysfunction (Warren et al., 1986, 
1987; Todd eta!., 1988; Singh eta!., 1993), and viral infections (Chess, 1977; 
Matrkowitz, 1983). Immune abnormalities, especially T cell-mediated dysfunction (Yonk 
et al., 1990), have been intensively investigated in autism. Abnormal T cell functions 
(Stubbs et al., 1977; Weizman et al., 1982), T cell number (Warren et al., 1986, 1990), 
and the helper/depression T cell ratio (Plioplys et al., 1994; Warren et al., 1995) are all 
altered in autistic subjects. 
CD4+ T cells, also known as helper T cells (Th), are at the core of T cell­
mediated immunity. There are two distinct subpopulations of CD4+ T cells (reviewed by 
Olsson, 1995). Thi cells activate macrophages, and inhibit B cells and are responsible for 
acute rejection during organ transplantation and for elimination of intracellular 
pathogens. Th2 cells activate B cells, and inhibit macrophages and cause antibody-related 
autoimmune reactions. CD4+ T cells control effector cells largely through the cytokines 
they secrete. The predominant cytokines secreted by Thi cells are interferon-y and IL-2 
and the predominant cytokines secreted by Th2 cells are IL-4, interleukin type 5 (IL-5), 
and interleukin type 10 (IL-10) (Mosmann and Sad, 1996). CD4+ T cell activation can 
lead to autoimmune diseases in human and animal models. Thl cell activation is also 
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responsible for organ-specific autoimmune diseases that include experimental 
autoimmune uveoretinitis and insulin-dependent diabetes (reviewed in Liblau et al., 
1995), and Thl -specific cytokines such as IL-2 and interferon-y are detected in 
autoimmune thyroiditis, type I insulin dependent diabetes mellitus, multiple sclerosis, 
peptic ulcers, and Crohn's disease (reviewed by Romagnani, 1995, 1996, 1997; Adorini 
and Sinigalia, 1997). In animal models, injection of activated Thi cells into naive animals 
generates experimentai autoimmune encephalomyelitis (EAE) (reviewed in Fabry et al., 
1994). Altered levels ofThl- or Th2-specific cytokines have also been observed in 
childhood obsessive-compulsive disorder and schizophrenia, suggesting an involvement 
of CD4+ T cells in these psychiatric diseases (Mittleman et al., 1997). 
The potential involvement of CD4+ T cells in autism has been investigated by 
examining cytokine expression patterns either in serum or in PBMC. Singh and his 
coworkers (Singh et al., 1991; Singh, 1996) reported that the Thl -specific cytokines IL-2, 
IL-12, and interferon-y were elevated in the serum of autistic individuals, whereas Gupta 
et al. (1998) reported that IL-4, a Th2-specific cytokine, was elevated in PBMC of 
autistic subjects. In this paper, we reexamined the issue of which type of CD4+ T cell, 
Thl or Th2, is involved in autism by using RT-PCR to measure IL-2, interferon-y, and 
IL-4 mRNAs present in PBMC. 
RT-PCR was chosen to assay cytokine expression because of its high sensitivity. 
This technique has been widely utilized for studies of cytokine expression in human 
autoimmune disorders (Di Fabio et al., 1994; Bost et al., 1995; Than et al., 1997). An 
assumption of the method is that mRNA levels are a reflection of active cytokine. In 
cases where this assumption has been examined, RNA levels have been shown to be a 
41 
good predictor of cytokine levels. For example, in a study of IL-10 expression in 
different human T cell lines, mRNA levels detected by RT-PCR were well correlated 
with IL-10 protein in serum, blood, and ascitic fluid as measured by enzyme-linked 
immunosorbent assay (ELISA) (Bost et al., 1995). 
The results reported here indicate that the Thi-specific cytokines IL-2 and 
interferon-y were elevated in autistic subjects and that the Th2-specific cytokine IL-4 was 
produced at detectable levels in only a single autistic individual. These results indicate 
that Thl cells are activated in autism. 
MATERIALS AND METHODS
Study Group 
This study included 24 autistic (22 males and 2 females) and 19 normal subjects 
(15 males and 4 females) (Table 2.1). Ages ranged from 2-19 years in the autistic group 
and from 7-16 years in the normal group. Diagnosis of autism was made by child 
psychiatrists according to parameters of American Psychiatric Association (1994). 
Isolation of Total RNA 
Blood was collected in heparin-coated tubes and peripheral blood mononuclear 
cells (PBMC) were isolated by histopaque centrifugation. The cells were washed with 
RPMI-1640, resuspended in 10% dimethyl sulfoxide and 90% fetal bovine serum (FBS), 
and cryopreserved at-80°C. For analysis, PBMC were thawed and cultured in RPMI-
1640 supplemented with 10% FBS and 10 µg/ml PHA (Gibco, BRL) for 5 days at 37°C 
in a humidified, 5% CO2 atmosphere. The PBMC were harvested and collected by 
Table 2.1 
Sex and Age of Subjects 
Autistic Normal 
Subject Sex Age Subject Sex Age 
#1 M 2 #1 M 7 
#2 M 2 #2 M 9 
#3 M 3 #3 M 9 
#4 F 4 #4 M 10 
#5 F 5 #5 M 10 
#6 M 5 #6 F 11 
#7 M 5 #7 M 11 
#8 M 6 #8 M 11 
#9 M 7 #9 F 11 
#10 M 7 #10 M 12 
#11 M 7 #11 M 12 
#12 M 7 #12 M 13 
#13 M 8 #13 F 13 
#14 M 8 #14 M 14 
#15 M 9 #15 M 14 
#16 M 11 #16 M 14 
#17 M 11 #17 M 15 
#18 M 11 #18 F 15 
#19 M 12 #19 M 16 
#20 M 13 
#21 M 13 
#22 M 14 
#23 M 16 
#24 M 19 
centrifugation and RNA was extracted from the pelleted cells using the Trizol RNA 
extraction kit according to the manufacturer's directions (Gibco, Gaithersburg, MD). 
Quantification of Cytokine mRNAs 
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cDNA was synthesized by random hexamer priming with Moloney murine 
leukemia virus reverse transcriptase (Promega, Madison, WI) using a kit according to 
manufacturer's directions (Boehringer Mannheim, GmbH, Germany). To minimize 
mRNA degradation, RNAase inhibitor at a final concentration of 1 unit/µl was added to 
the cDNA synthesis reaction. 
Interferon-y and IL-4 mRNA levels were determined by RT-PCR using 
commercial kits purchased from Clontech (Palo Alto, CA). These kits use specific 
"mimic" cDNAs added at known concentration to the reaction. The mimic cDNAs are 
cloned versions of the interferon-y and IL-4 sequences that contain a small insertion to 
distinguish their amplification products from that of the endogenous sequences. These 
mimics and the cDNA synthesized from endogenous mRNA compete for the same primer 
set and other components of the PCR system. The sequences of oligonucleotide primers 
used in this study are given in Table 2.2. Precautions to avoid contamination in the PCR 
included the use of aerosol barrier tips and RNase inhibitor treatment of pipets, 
glassware, and bench surfaces. Negative controls lacking template DNA were included in 
all PCR analyses. In no case was there evidence of spurious amplification. 
For competitive RT-PCR of interferon-y and IL-4, 2 µl of cDNA synthesized 
from PBMC mRNA was placed into five tubes. Each tube contained a primer pair and 2 
µl of a 1 :3 dilution series of mimic cDNA with a starting amount 5.1 x 107 molecules of 
Table 2.2 
Oligonuleotide Primers Used in the Cytokine Study 
Cytokine Sequences 
Interferon-y 5' 5'-GCA TCG TTITGGG ITCTCITGGCTGTT ACTGC-3' 
Interferon-y 3' 5'-CTCCTTTITCGCTTCCCTGITTT AGCTGCTGG-3' 
IL-4 5' 5'-CGGCAACITTGACCACGGACACAAGTGCGAT A-3' 
IL-4 3' 5'-ACGTACTCTGGITGGCITCCITCACAGGACAG-3' 
IL-2 5' 5'-AACTCCTGTCITGCA ITGCA-3' 
IL-2 3' 5'-GTGTTGAGA TGA TGCTITGAC-3' 
Actin 5' 5'-ATGTTTGAGACCTTCAACAC-3' 
Actin 3' 5'-CACGTCACACTTCA TGATGG-3' 
Size 
PCR 
427 bp 
344 bp 
441 bp 
489 bp 
Mimic 
570 bp 
504 bp 
.i:,.. 
.i:,.. 
45 
interferon-y and 5.6 x 106 molecules ofIL-4. Mimic cDNAs and primers were 
purchased from Clonetech (Palo Alto, CA). IL-2 mRNA levels were measured relative to 
actin mRNA according the method of Haraguchi et al. (1995). Actin mRNA expression is 
assumed to be constitutive. Separate PCRs were performed to amplify IL-2 and actin 
cDNA, but analyzed in the same condition. 
PCR was performed in a 15-µl mixture containing 10 mM Tris (pH 8.3), 50 mM 
KCl, 1.2 mM MgCh, 1 mM dNTP, 1 unit Taq DNA polymerase (Fisher Scientific, 
Pittsburgh, PA) and 45 pmol of each primer pair. PCR was carried out with an initial 5-
minute denaturation at 94°C followed by 30 cycles of the following profile: 1 minute at 
94°C, 1 minute at 64°C, and 2 minutes at 72°C. Pilot experiments were performed to 
establish conditions under which the PCR remained in exponential phase. Four µl of each 
PCR product was analyzed by electrophoresis through 1.5 % agarose gels. Gels were 
stained with ethidium bromide, visualized under UV light, and photographed with 
Polaroid 667 film. 
The levels of interferon-y and IL-4 mRNA were determined by comparison 
between the endogenous and mimic cDNA amplification products. Five different PCRs in 
which each PCR containing a different dilution of the mimic cDNA were run for each 
cytokine from each subject. Whenever the densities of the mimic and endogenous cDNA 
products matched, this indicated that the starting target cDNA concentrations were equal 
to that of their corresponding mimic cDNA. Tests ofthis method using a fixed and 
known amount of endogenous cDNA and varying amounts of mimic cDNA verified the 
accuracy of this method (data not shown). Relative levels ofIL-2 were determined by 
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comparison of the intensity of the amplification products of the IL-2 and actin mRNAs 
from the same individual. This ratio was termed arbitrary optical density units (AODU). 
The photograph of the stained agarose gel was scanned and the intensities of the bands 
were determined using a densitometer (Biosoft Image System, Ferguson, MO). Mean 
values for each cytokine present in the autistic and normal groups were calculated and 
evaluated for statistically significant differences using Student's t test. 
The levels ofThl- and Th2-specific cytokine mRNAs in the autistic and normal 
groups were compared in two different ways. In the first method, cytokine levels were 
averaged for the autistic and normal groups and the significance of these differences was 
analyzed using Student's t test. The second method compared the number of individuals 
in each group that expressed a particular cytokine to any detectable level and the 
significance of intergroup differences was assessed by the x,2 test. These independent 
methods of analysis provide a measure of confidence regarding differences between 
autistic and normal individuals. 
RESULTS 
Levels of the Th I-specific cytokines interferon-y and IL-2 are shown as scatter 
plots in Figures 2.1 and 2.2, respectively, and are given in Table 2.3. Because interferon-y 
mRNA levels varied widely in both groups, they are shown as log 10-transformed values 
in Figure 2.1. The mean level of interferon-y expression was 2.5-fold higher in the 
autistic group and this difference from the normal group was significant (p < 0.05). As 
for interferon-y, there also is considerable variability in IL-2 expression levels in both 
groups. The autistic group expressed an average 3-fold higher level oflL-2 mRNA 
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Fig. 2.1. lnterferon-y mRNA expression in autistic and control groups. The log 10-
transformation of interferon-y mRNA molecules per µg of total RNA is plotted for each 
autistic and normal subject. Any value below the break mark ( //) indicates undetectable 
levels of expression. The black horizontal bars (-) show the mean of the group, and the 
sample size in each group is given by the n value. 
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Table 2.3 
Cytokine Expression in Autistic and Normal Subjects 
Group 
No. Detectable 
% detectable 
x
2 test 
µ± SD
a
Student's t test 
Interf eron-y 
Autistic Normal 
15/24 5/19 
63% 26% 
P < 0.025 
12400 ± 7900b 4500 ± 8200b
P < 0.05 
aMean ± standard deviation. 
bCytokine molecules/µg total RNA isolated from PBMC.cThe ratio between IL-2 and actin mRNA expression. 
dNot applicable. 
IL-2 
Autistic Normal 
22/24 8/19 
92% 42% 
p < 0.005 
0.60 ± 0.43c 0.18 ± 0.20c
p < 0.0002 
IL-4 
Autistic Normal 
1/24 5/19 
4% 26% 
p < 0.005 
240 ± 112b 1300 ± 1960b
NAd
� '° 
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than did the normal controls (p < 0.0002). The expression of both of major Thl-
specific cytokines in the autistic group indicates that Thl CD4+ T cells are activated in 
many autistic individuals. 
Levels of the Th2-specific cytokine IL-4 mRNA are shown as a scatter plot in 
Figure 2.3 and are given in Table 2.3. Only one of the autistic subjects and 5 of the 
normal subjects expressed detectable levels oflL-4 mRNA. Because of the low numbers 
of individuals expressing IL-4 in each group, Student's t test could not be used to analyze 
these results. 
As shown in Table 2.3, the numbers of individuals in each group who expressed 
particular cytokines are also displayed. Interferon-y was detected in 15 of24 (62.5%) 
autistic subjects and 5 of 19 (26.3%) control subjects. This difference was significant (p < 
0.025 by x 2). IL-2 was detected in 22 of24 (91.7%) autistic subjects and 8 of 19 (42.1%)
normal controls. This difference was also significant (p < 0.005 by x2). In contrast to the 
Thl -specific cytokines, a higher number of control subjects expressed the Th2-specific 
cytokine IL-4 than did autistic subjects. Five of 19 (26%) control subjects and 1 of 24 
(4%) autistic subjects expressed IL-4. This difference also was significant (p < 0.005 by 
X 2). 
The mean age for the autistic and normal study groups was 8.5 and 11.9 years, 
respectively. Although Student's t test evaluation of this age difference indicated it was 
not significant, the possibility that the elevated cytokine expression in the autistic group 
was due to the younger average age of these individuals was examined. The levels of 
IL-2 and interferon-y were plotted against subject age and are show shown in Figure 2.4. 
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There was no significant correlation between cytokine expression and age (r values 
ranged between - 0.06 and+ 0.27). These results indicate that the difference in cytok.ine 
expression between groups was not age-related. The low frequency of individuals 
expressing IL-4 made age-specific comparisons meaningless in these study groups. 
Since there were more females in the normal control group than in the autistic 
group, the possibility of a gender-specific difference in cytokine expression was 
examined by comparing the expression of IL-2 and interferon-y in males and females 
within each study group and in the two groups as a whole. Student's t test indicated that 
gender played no role in the expression of these cytokines ( data not shown). The low 
frequency of individuals expressing IL-4 made gender-specific comparisons meaningless 
in these study groups. 
DISCUSSION 
The current study supports an association between autism and increased 
expression of Th I-specific cytokines. A significant elevation of interferon-y and IL-2 
mRNA levels and a higher frequency of individuals expressing interferon-y and IL-2 
mRNAs was found in this study group of 24 autistic subjects. This indicates that there is 
a Th 1 type of immune response in many autistic individuals. At the same time, there was 
almost no expression of IL-4 in the autistic group. This result argues against a Th2 type 
of response in the autism. 
The results reported here agree with conclusions drawn by Singh and associates 
who used an ELISA-based method of cytokine analysis and found increased levels of IL-
2 and IL-12 in autistic individuals (Singh et al., 1991; Singh, 1996). Like IL-2, IL-12 is 
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an indicator of a Th 1 response. Our and Singh' s results contrast with those of Gupta et 
al. ( 1998), who reported a Th2 response in autistic individuals. Differences exist between 
all these studies and include: 1) Gupta and associates' use of fresh rather than 
cryopreserved PBMC; 2) the younger age of study subjects investigated by Gupta and 
associates; and 3) the use of different methods (RT-PCR, ELISA and flow cytometry) to 
assess cytokine production. It is unlikely that the use of cryopreserved rather than fresh 
cells account for the different results because cryopreservation of PBMC has been 
reported not to affect cell activation markers, viability, T cell function, preferential 
stimulation of CD4+ vs. CD8+ T cells ( van Lunzen et al., 1995), or the repertoire of T 
cell receptors p chains (see Appendix A). Difference in the subject age also does not 
appear to be an important factor leading to the different results of these studies as we 
showed that cytokine mRNA expression and age were not related (Figure 2.4). 
Examining cytokine levels in a single study group using the varied methods of all these 
investigations may clarify the reasons for the different conclusions. Moreover, a long­
term study from early childhood to adulthood would illuminate whether there is a stage­
specific switch in the Th 1-Th2 response observed in autism. 
Our results extend a growing body of observations that relate abnormal immune 
functions to autism. Altered helper T cell function has also been reported in other 
pediatric psychiatric diseases, including childhood-onset schizophrenia, obsessive­
compulsive disorder and attention deficit hyperactivity disorder (Mittleman et al., 1997). 
One possible mechanism linking Thi CD4+ T-cell activation in the peripheral blood and 
autism is the ability of helper T cells to cross the blood-brain barrier (Wekerle et al., 
1986, 1994). Once within the central nervous system these cells could trigger an 
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inflammatory response that may damage areas of the brain critical to the development 
of autism. Although the work reported here does not allow drawing the conclusion that a 
causal link exists between the Th 1 immune response and autism, the repeated association 
between autism and immune system abnormalities demands closer examination of this 
central question. 
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CHAPTER3 
PREFERENTIAL EXPRESSION OF THE T CELL RECEPTOR 
V-f3 CHAIN SUBTYPE V-f3 13 IN AUTISM
ABSTRACT 
59 
T cell-mediated immune abnormalities are associated with autism. The possibility 
that specific T cell clones are expanded in autism was investigated in this work by 
analyzing the expression of the 24 major T cell receptor (TCR) V-f3 chains in a group of 
11 autistic and 9 normal subjects. The expression of these V-f3 chains serves as a marker 
for T cell clone expansion. Our results indicated that autistic subjects predominantly 
expressed V-f3 13. The difference in V-f3 13 expression relative to the control group was 
significant (p < 0.01; Wilcoxon's rank sum test). The expression ofV-f3 13 was especially 
prevalent in the subgroup of autistic individuals who carried the DR4 or DRl alleles that 
are common in autism. V-f3 19 and 22 are underrepresented (p < 0.01 and p < 0.05, 
respectively) in the autistic group relative to the controls. This is the first report of an 
alteration of the TCR repertoire in autism and is consistent with many previous reports that 
immune system abnormalities are involved in autism. The prevalence of expanded V-f3 13-
expressing T cell clones strengthens evidence that at least some cases of autism are a result 
of an autoimmune disorder. 
INTRODUCTION 
Multiple causes have been postulated for the etiology of autism, including genetic 
factors, immune dysfunction (Warren et al., 1986), and viral infections (Chess, 1977; 
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Deykin and Macmahon, 1979; Markowitz, 1983). Immune abnormalities, especially T 
cell-mediated dysfunction, have been intensively investigated in autism. Relevant 
findings associated with autism include increased serum levels of interleukin type 2 (IL-
2), interleukin type 12 (IL-12) and interferon-y (Singh, 1996), decreased T cell responses 
to mitogens (Stubbs et al., 1977), depressed CD4+ T cell functions (Y onk et al., 1990), 
decreased natural killer functions (Warren et al., 1990), and increased expression of the 
DR+ surface marker (Warren et al., 1990; Plioplys et al., 1994). 
T cell clone expansion is a hallmark of autoimmune diseases. A panel of these 
documented autoimmune diseases with T cell clone expansion includes multiple sclerosis 
(Wucherpfennig and Hatler, 1995; Lozeron et al., 1998), type I diabetes (Atlan-Gepner et 
al., 1997), systemic lupus erythematosus (Furukawa et al., 1996; Holbrook et al., 1996; 
Mato et al., 1997), Kawasaki disease (Abe et al., 1993), sarcoidosis (Moller et al., 1988), 
microscopic polyarteritis (Simpson et al., 1995), and rheumatoid arthritis (Jenkins et al., 
1996; Davey and Munkirs, 1993). In every one of these disorders, one or a few T cell 
clones form the predominant activated T cell population. Many other diseases, including 
autism, are suspected to have an autoimmune basis and show T cell clone expansion. 
Expanded T cell clones usually are identified on the basis of the T cell receptors 
they express. The common T cell receptor is a heterodimer of a and p chains. The 
specificity of antigen interaction with the TCR is controlled largely by the variable region 
(V) of the p chain (Wucherpfennig and Hatler, 1995). Characteristic patterns of T-cell V­
P expression have been associated with autoimmune diseases (McMurray et al., 1996). 
Two methods are available for the detection of specific V-P chains: flow cytometry and 
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reverse transcription-based polymerase chain reaction (RT-PCR). RT-PCR has the 
advantage of greater sensitivity (Than et al., 1997) and now is the method of choice. 
The studies reported here use RT-PCR of mRNA isolated from peripheral blood 
to learn if particular T cells clones are expanded in autism. The expression patterns of the 
24 major V-P chains were examined in a group of 11 autistic and 9 normal individuals. 
V-P 13 was the predominant V-P chain expressed by autistic individuals, indicating the
expansion of a subset of T cell clones in many cases of autism. The association between 
V -P 13 expression and autism was even more pronounced when the subgroups of 
individuals who were positive for the antigen-presenting DR alleles that are associated 
with autism (DR4 or ORI) were analyzed separately. The expansion ofV-p 13-expressing 
T cell clones in autistic patients provides further evidence that at least some cases of autism 
are a result of an autoimmune disorder. 
MATERIALS AND METHODS 
Study Subjects 
This study examined 11 autistic and 9 normal subjects whose gender, age and DR 
types of the study subjects are summarized in Table 3.1. The 11 autistic subjects were all 
male with a mean age of 11.5 years and the diagnosis of autism was accomplished by 
psychiatrists according to criteria for autism of the American Psychiatric Association 
( 1994 ). The male to female ratio of autistic individuals in the general population is about 
4: 1 (Shaner, 1997). Seven autistic subjects had the human leukocyte antigen (HLA) 
alleles DR4 or DRl that increase susceptibility to autism. The normal subjects (6 male, 3 
Table 3.1 
Sex, Age and DR Types of the Subjects for V-P Analysis 
Autistic Normal 
Subject Sex Age DR types a Subject Sex Age DR types a 
#1 M 6 3,4 #1 M 8 9, 12 
#2 M 10 1, 4 #2 F 10 3,4 
#3 M 10 4, 15 #3 F 10 l, 7 
#4 M 10 4, 7 #4 M 10 3, 13 
#5 M 11 1, 11 #5 M 11 4, 12 
#6 M 11 3, 10 #6 F 12 l, 15 
#7 M 13 4, 13 #7 M 13 11, 12 
#8 M 13 3, 10 #8 M 14 4, 15 
#9 M 14 12, 13 #9 M 15 7,9 
#10 M 14 7, 16 
#11 M 15 4, 13 
�umbers represent HLA DR types in short format where 1 = DRl, 
3 = DR3, 4 = DR4, etc.
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female) had a mean age of 11.4 years. Five of these normal subjects had either the DR4 
or ORI allele. Child psychiatrists diagnosed autism according to diagnostic parameters of 
American Psychiatric Association ( 1994 ). 
HLA Typing 
Blood was collected into heparin-coated tubes and peripheral blood mononuclear 
cells (PBMC) were isolated by histopaque centrifugation. HLA typing was performed by 
the microlymphocytotoxicity assay using a kit from One Lambda, Inc. (Canoga Park, 
CA). 
Total RNA Isolation and cDNA Synthesis 
PBMC isolated by Ficoll-Hypaque centrifugation were stimulated with 
phytohemagglutinin (PHA) (10 µg/ml) (Gibco, BRL). The cells were cultured in the 
presence of PHA at 3 7°C in a humidified 5% CO2 atmosphere for 5 days before 
extraction of total RNA. RNA was extracted from 5 x 105 PBMC using a kit according to 
manufacturer's instructions (Trizol reagent kit, Gibco, Gaitherburg, MD). The resulting 
total RNA was dissolved in 30 µl of sterile H2O and its concentration was determined by 
absorbance at OD260nm· 
To synthesize cDNA, 2 µg of total RNA was reverse-transcribed using a kit 
according to manufacturer's instructions (Boehringer, Mannheim, GmbH, Germany). The 
20-µl reaction contained 0.1 OD26o of random hexamers, 40 units of RNase inhibitor, I 
mM of each dNTP, 50 mM Tris (pH 8.3), 75 mM KCI, 3 mM MgCh, IO mM DTI, and 
200 units of Moloney murine leukemia virus (MML V) reverse transcriptase (Promega, 
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Madison, WI). The mixture was incubated at 3 7°C for 2 hours. 
Precautions were taken to avoid mRNA degradation and contamination. cDNA 
synthesis was always performed immediately following RNA isolation to minimize 
potential for mRNA degradation. An RNase inhibitor (Promega, Madison, WI) was also 
added at 1 unit/µl to the cDNA synthesis reaction. Solutions, glassware, pipets, and bench 
surfaces were treated with diethyl pyrocarbonate to inactivate RNases. 
TCR V-[J Chain Expression 
The cDNA resulting from reverse transcription was divided equally into 24 tubes, 
each containing a 5' TCR V-p-specific sense primer, a common 3' primer that annealed to 
the constant region of the p chain, and 0.1 pg of competitor cDNAs. The competitor 
cDNAs were kindly provided by Dr. D. Spinella (Chugai Biopharmacetics, San Diego, 
CA) and served as internal controls of primer efficiency (Spinella and Robertson, 1994 ). 
The 24 competitor cDNAs were constructed by inserting an 86-bp Xho II fragment from 
pUC 19 into a unique Bgl II site in the constant region of the p chain. 
PCR was performed in a 15-µl reaction that contained 10 mM Tris (pH 8.3), 50 
mM KCI, 1.2 mM MgCb, 1 mM of each dNTP, 1 unit Taq DNA polymerase (Fisher 
Scientific, Pittsburgh, PA), and 45 pmol of each primer. PCR was carried out with an initial 
5 minutes of denaturation at 94 °C, followed by 30 cycles of the profile: l minute at 94 °C, 
1 minute at 58 °C, and 1 minute at 72 °C. After the PCR, 4 µI of the reaction was analyzed 
by electrophoresis through a 2% agarose gel. The gel was stained with ethidium bromide 
and photographed under UV light, and the intensity of each band in the photograph was 
quantified using Biosoft Image System (Biosoft, Ferguson, MO). 
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The relative expression of each V-P chain was determined according to 
Spinella and Robertson (1994). A value of 1.0 was assigned to the most intense 
competitor band obtained in the 24 PCR reactions run from a single individual and all 
other 23 competitor bands were normalized relative to this intensity value. These ratios 
represent the amplification efficiency of the 24 primer pairs. Next, the intensity of the 
endogenous V-P chain cDNA product was divided by the amplification efficiency of the 
primer pair. These 24 values are referred to as corrected expression. Corrected expression 
values were normalized relative to the highest corrected expression value in the set of 24 
V-P chains. Each normalized value is referred to as a relative expression index (REI) and
provides an estimate of the relative amount of each V-P chain mRNA expressed in an 
individual. Negative controls lacking template DNA were included in all PCR analyses. 
In no case was there evidence of spurious amplification. 
Wilcoxon's rank sum test (Harnett, 1982) was applied to estimate the significance 
of differences in the rank order of V-P chain expression between the autistic and normal 
groups. 
Cytokine Expression 
Interferon-y and interleukin type 4 (IL-4) mRNA levels were determined using 
kits supplied by Clontech (Palo Alto, CA). Two µl of cDNA synthesized from PBMC 
mRNA was placed into five tubes. Each tube contained a cytokine-specific primer pair 
and 2 µl of a member of a 1 :3 dilution series of competitor cDNA. Five independent 
reactions were performed using conditions described above for each subject for each 
cytokine (see Chapter 2). The IL-2 mRNA levels were measured relative to actin mRNA 
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according the method of Haraguchi et al. ( 1995). Actin mRNA expression was 
assumed to be constitutive. Separate PCRs were performed to amplify IL-2 and actin. 
The PCR products were analyzed by electrophoresis through a 1.5% agarose gel and 
photographed under UV light. The amount of IL-4 and interferon-y mRNA was 
determined by finding a lane in which the intensities of the competitor and endogenous 
cDNA products matched. This occurred when the amounts of starting competitor and 
endogenous cDNA were equal. Since there was a known amount of competitor cDNA 
added to each reaction, this gave the amount of starting endogenous cDNA. Relative 
expression levels ofIL-2 were determined by comparison between the intensity of the 
amplification products of the IL-2 and actin mRNAs from the same individual. This ratio 
was termed arbitrary optical density units (AODU). Student's t test was used to analyze 
the significance of differences between the average AODU in the autistic and normal 
groups. 
RESULTS 
Competitive RT-PCR was used to study TCR V-p expression in autistic subjects. 
Figure 3.1 shows a representative gel displaying RT-PCR products ofTCR V-p chain 
mRNA from a autistic subject. Two DNA bands are visible in each lane of the gel (Figure 
3.1 ). The smaller band is generated from target cDNA and the larger one is derived from 
competitor cDNA. As expected, the products from competitor cDNAs were 86-bp larger 
than the corresponding products of endogenous mRNAs. The REI values for each V-P 
derived from analysis of this gel are shown in Figure 3 .2. V-P 3 and V -P 13 are the 
predominant V-P forms expressed in this individual. This indicates that there was an 
Lane I 2 3 4 5 6 7 8 9 IO I I 12 M 13 14 15 16 I 7 18 19 20 21 22 23 24 
Fig. 3.1. RT-PCR analysis of V-� chain expression in a single individual. 
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expansion of T cells clones that express these forms of the TCR p chain in this 
individual. Similar analyses were performed for all subjects of the study. 
The mean REI for each V-P chain was calculated in the autistic and normal groups. 
These values were compared between the groups and are shown in Table 3.2. Inspection of 
the results shows that in the autistic group V-P 13 was found at appreciably higher 
frequency and V-P 14, 15 , 19 , and 22 were found at appreciably lower frequencies. The 
significance of these differences was analyzed by Wilcoxon's rank sum test, a statistical 
test that compares the rank order of V-P chain expression between the two groups, 
according to the methods of Jenkins et al. (1996). As shown in Table 3.2 , there was a 
significant increase of V-p 13 expression (p < 0.01) and a significant decrease in V-p 19 (p 
< 0.0 l) and V-p 22 (p < 0.05) in the autistic subjects. Differences in the relative expression 
of other V-p chains between groups were not significant according to this measure. 
Individuals who possess either the DR4 or ORI allele are at greater risk of 
developing autism (Warren et al., 1992). This led us to examine whether V-P chain 
expression patterns would differ between the subgroups of autistic and normal subjects 
who express either DR4 or ORI. Application of Wilcoxon's rank test showed that there 
was significantly increased expression ofV-p 13 in autistic subjects (n = 7; p < 0.01) 
relative to normal subjects (n = 5) with the mear.i REI of 0.86 for V-p 13 in the autistic 
group and 0.15 in the normal group. In this comparison of subgroups of DR4 or ORI 
positive individuals, there was no significant difference in the relative expression of V-p 19 
and 22 as seen in the comparison of all autistic and normal individual s (Table 3.3). These 
results showing significant expansion ofV-P expressing T cells clones in autistic 
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Table 3.2 
TCR V-P Expression in Autistic and Normal Subjects 
Autistic (n = 11) Nonna! (n = 9) Wilcoxon's 
V-P REia (µ ± S.D.'J REI\µ± s.o.'J Rank Sum Test 
1 0.18±0.18 0.19 ± 0.18 
2 0.27 ± 0.18 0.30 ± 0.34 
3 0.33 ± 0.33 0.33 ± 0.41 
4 0.06 ± 0.06 0.14 ± 0.32 
5 0.31 ± 0.28 0.33 ± 0.39 
6 0.47 ± 0.31 0.32 ± 0.24 
7 0.18 ± 0.13 0.19±0.16 
8 0.31 ± 0.29 0.32 ± 0.32 
9 0.23 ± 0.28 0.21 ± 0.22 
10 0.08 ± 0.08 0.08 ± 0.12 
11 0.11 ± 0.15 0.07 ± 0.09 
12 0.10 ± 0.11 0.08 ± 0.07 
13 0.92 ± 0.17 0.34 ± 0.39 p< 0.0lc 
14 0.12±0.12 0.29 ± 0.28 
15 0.07 ± 0.09 0.24 ± 0.32 
16 0.17±0.19 0.06 ± 0.06 
17 0.12±0.12 0.18 ± 0.31 
18 0.08 ± 0.09 0.06 ± 0.06 
19 0.02 ± 0.03 0.06 ± 0.06 p< 0.0lc 
20 0.08 ± 0.14 0.15±0.16 
21 0.33 ± 0.28 0.29 ± 0.26 
22 0.06 ± 0.08 0.25 ± 0.22 p< o.osc 
23 0.22 ± 0.23 0.21 ± 0.23 
24 0.05 ± 0.05 0.08 ± 0.14 
3Relative expression index. 
bMean ± standard deviation. 
cOnly values that indicate a significant difference between group 
are shown. 
Table 3.3 
TCR V-P Expression in Autistic and Normal Subjects Expressing DR4 or DRl 
Autistic (n = 7) 
V-P REi
a (µ ± S.D.b) 
0.19 ± 0.22 
2 0.24 ± 0.22 
3 0.31 ± 0.39 
4 0.07 ± 0.08 
5 0.26 ± 0.31 
6 0.50 ± 0.36 
7 0.17 ± 0.16 
8 0.34 ± 0.37 
9 0.26 ± 0.35 
10 0.09 ± 0.09 
11 0.15±0.18 
12 0.12 ± 0.14 
13 0.86 ± 0.20c
14 0.11 ± 0.13 
15 0.09 ± 0.10 
16 0.19 ± 0.23 
17 0.13 ± 0.12 
18 0.09±0.10 
19 0.03 ± 0.04 
20 0.11 ±0.17 
21 0.37 ± 0.34 
22 0.09 ± 0.09 
23 0.30 ± 0.25 
24 0.06 ± 0.06 
aRelative expression index. 
bMean ± standard deviation. 
Normal (n = 5) 
REia (µ ± S.D.� 
0.16±0.18 
0.36 ± 0.40 
0.34 ± 0.41 
0.22 ± 0.44 
0.26 ± 0.42 
0.28 ± 0.25 
0.15 ± 0.13 
0.35 ± 0.35 
0.15±0.16 
0.06 ± 0.08 
0.05 ± 0.06 
0.07 ± 0.05 
0.15 ± 0.15c
0.23 ± 0.21 
0.26 ± 0.42 
0.03 ± 0.03 
0.04 ± 0.02 
0.06 ± 0.06 
0.05 ± 0.04 
0.12 ± 0.16 
0.15 ± 0.11 
0.26 ± 0.22 
0.14 ± 0.10 
0.03 ± 0.04 
cHighly significant difference (p < 0.01; Wilcoxon's rank sum test). 
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individuals correlate well with a previous finding that showed activation of Thl cells 
in the disease (see Chapter 2). 
Six of the autistic subjects in this study were coparticipants in the study that 
examined the profiles of IL-2, interferon-y and IL-4 expression as markers for activation 
ofThl or Th2 cells (Chapter 2). A cross-study comparison was made using this group of 
autistic subjects to learn if the correlation between the expansion of V-P 13-expresssing T 
cell clones and elevated expression ofThl -specific cytokines (interferon-y and IL-2) 
occurred in the same individuals. The relative expression level of V-P 13 was 
significantly higher in this group of autistic individuals (n = 6) (see Table 3.4) but not in 
the normal controls (n = 9). As shown in Table 3 .4, levels of the Th I-specific cytokines 
IL-2 and interferon-y are also elevated in the same group of autistic individuals. This 
correlation of expansion of V-P 13-expresssing T cell clones and elevated expression of 
IL-2 and interferon-y in the same set 0f autistic individuals suggests that both these 
processes may cooperatively interact in the pathogenesis of autism. 
DISCUSSION 
In this study, we showed that in many autistic individuals elevated V-p 13 chain 
expression is elevated. This is the first report of an alteration of the TCR repertoire 
associated with autism. This finding is consistent with many previous reports of altered 
immune responses in autism. Expression of particular T cell clones occurs in many 
autoimmune diseases (Marchalonis et al., 1994; Schneider and Gronvik, 1995; Wooley 
and Cingel, 1995), and our finding of V-P 13 expansion in autism provides evidence that at 
least some cases of autism are a result of autoimmunity. 
Table 3.4 
Cytokine and V-P Chain Expression in Six Autistic Subjects 
DR 
Group Subject Sex Types 
Autistic #1 M 4, 7 
#2 M I, 4 
#3 M 12, 13 
#4 M 1, 11 
#5 M 3, 10 
#6 M 4, 13 
Autistic subjects (µ ± SDd) 
Normal subjects (µ ± SD
d
) 
Student's t test 
aIL-2 mRNA levels relative to actin mRNA levels. 
bRelative expression index. 
�ot detectable in the assay. 
dMean ± standard deviation. 
Age Interferon-y mRNA Molecules 
(years) IL-2/Actina per µg of Total RNA 
19 0.85 19,293 
9 0.42 N.D.c
15 0.31 N.D.c
11 0.65 19,293
11 1.33 519,280
13 0.05 19,293
0.58 ± 0.45 15,900 ± 15,900 
(n = 6) (n = 6) 
0.18±0.20 4,500 ± 8,200 
(n = 19) (n = 19) 
p < 0.01 p < 0.01 
V-P 13
(REI'J
1.00 
1.00 
0.50 
1.00 
1.00 
0.80 
0.88 ± 0.20 
{n = 6) 
0.34 ± 0.39 
(n = 11) 
p < 0.01 
-....} 
I.H 
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The TCR repertoire is determined by many factors, including genetic factors, 
major histocompatibility complex (MHC)-mediated selection by antigens during T cell 
development in the thymus, and by infection (Islam et al., 1996). TCR repertoires are 
significantly altered in many autoimmune disorders (Marchalonis et al., 1994; Schneider 
and Gronvik, 1995; Wooley and Cingel, 1995). For example, in rheumatoid arthritis, V-13 
17 expression predominates (Davey and Munkirs, 1993; Fischer et al., 1996), and in 
multiple sclerosis T cell clones that express V-13 8 predominant (Wucherpfennig and 
Hafter, 1995). It is tempting to speculate that a similar link exists between the expansion 
of V-13 13-expressing T cell clones and the development of autism. 
The expression of V-13 13 was especially prevalent in the group of autistic 
individuals who carried the DR4 or DRl alleles that are common in autism. In many 
autoimmune diseases, including insulin -dependent diabetes mellitus, rheumatoid arthritis, 
and multiple sclerosis, there is a strong association between the disease and the 
expression of a particular DR molecule (Geha et al., 1994). These autoimmune diseases 
also show preferential expression of particular V -13 chains that indicate expansion of 
specific T cell clones (Grunewald et al., 1998; Navaneetham et al., 1998; McKee et al., 
1999). One model that links these observations postulates that specific DR molecules 
present some antigens in a way that is recognized preferentially by a single form of TCR. 
If the DR-antigen complex mimics a self-antigen, the T cell clone that is expanded by 
stimulation with a foreign antigen could produce an autoimmune response that targets 
host tissue specific to the disease. This may be the case in the relationship between DR4 
or DRl and V-p 13-expressing T cells in autism. 
75 
There is a correlation between dominant expression of V-p 13 and the expression 
of Thl-specific cytokines IL-2 and interferon-yin the 6 autistic individuals who 
participated in this study and an earlier investigation of cytokine expression study (Chapter 
2). Enhanced cytokine expression and expansion ofT cells that express V-P 13 may be tied 
together in a positive feedback loop in which the cytokines stimulate T cell proliferation 
and in turn the T cells produce yet more Thl specific cytokines. IfV-P 13-expressing T 
cells are involved in an autoimmune response in autism, elevated cytokine expression is 
likely to exacerbate symptoms of the disease. 
The identification of V -P 13 as the predominant V-P chain expressed in most 
autistic individuals may aid in the identification of autoantigens that are targeted in the 
disease. One approach to this goal would be to isolate the V-p 13-expressing T cell clones 
from autistic patients and test their ability to be stimulated by self-antigens. 
If the finding of an association between autism and expansion of T cell clones 
expressing V-P 13 is general, then there is the possibility for immune therapy based on 
deletion of these specific T cell clones. Such an approach has been successfully 
demonstrated in animal models of multiple sclerosis, where treatment with antibody 
directed against the predominant TCR V-P 8 chain dramatically reduced mortality 
associated with the disease (Gold et al., 1997; V andenbark et al., 1992). 
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CHAPTER4 
INVESTIGATION OFT CELL RESPONSE TO EPITOPES OF 
SUSPECTED PATHOGENS IN AUTISTIC PATIENTS 
ABSTRACT 
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This communication reports tests of two models for autism that are based on T 
cell-mediated immune abnormalities. One model postulates that infections in 
compromised individuals allow pathogen persistence to cause central nervous system 
(CNS) damage that leads to autism. A prediction of this model is that autistic individuals 
will show a reduced immune response to the pathogen that triggered the disease. T cell 
epitopes derived from pathogens suspected to cause autism were examined for their 
ability to induce T cell proliferation in autistic and normal subjects. As a group, the T 
cells of autistic subjects did not show an altered response to peptides derived from rubella 
virus, herpes simplex virus type 1 (HSV-1 ), cytomegalovirus (CMV), Epstein-Barr virus 
(EBV), and Clostridium tetani. Increased T cell proliferation in autistic individuals to a 
peptide derived from influenza A virus was noted. These results do not support a model 
in which autism is caused by an immune tolerant response to any of the pathogens tested 
here. Another model of autism tested here is that autism is induced by pathogens that 
possess epitopes identical to the hypervariable region 3 (HVR-3) of the human leukocyte 
antigen (HLA) DR4 or DRl alleles that are prevalent in autism. This model proposes that 
T cell-mediated immunity is ineffective against these pathogens so they persist and 
ultimately cause CNS damage that produce autism. Peptides derived from the 
Escherichia coli (E. coli) dna J and the Epstein-Barr virus (EBV) glycoprotein (gp) 110 
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that contain sequences identical to the HVR-3 of the DR4 and DRl alleles were 
examined for their ability to induce T cell proliferation in DR4 or DRl positive and 
negative autistic and normal subjects. There was no relationship between possession of 
DR4 or DRl allele and the ability to respond to either peptide. Although the results of 
these studies do not provide support for involvement of a specific pathogen in autism, the 
average T cell proliferative activity of autistic subjects was lower than that of normal 
individuals. This result is consistent with prior reports that show there is a reduced T cell­
mediated immune response in autism. 
INTRODUCTION 
Infections have long been associated with autism (Chess, 1977; Stubbs, 1976), 
although the mechanism that couples infections with the development of autism is 
unknown. Pathogens associated with autism by epidemiological investigations mainly 
include rubella virus, HSV-1, and CMV. In addition, immunization with rubella and 
tetanus vaccines has been proposed to cause autism in a small number of individuals 
(Munyer et al., 1975; Rossier et al., 1977). A potential link between infection and autism 
is the depression of immune functions that is often seen in autistic subjects. These 
reduced immune system functions include lower numbers of CD4+ T cells (Y onk et al., 
1990; Warren et al., 1990), decreased amounts of complement C4B (Warren et al., 1995), 
reduced responsiveness to mitogens (Yonk et al., 1990; Warren et al., 1986), depressed 
functions of natural killer cells (Warren et al., 1987), and abnormal cytokine profiles 
(Singh et al., 1991; Singh, 1996; Gupta et al., 1998) indicative of defective T cell 
functions. One model that relates infection and autism postulates that if pre- or postnatal 
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infections occur in individuals with a reduced ability to clear the infectious agent, this 
will allow the pathogen to persist and cause CNS damage that leads to autism. One 
prediction of this model is that autistic individuals will show a reduced T cell-mediated 
immune response to the pathogen that triggered the disease. This prediction was tested 
here by assessing the T cell proliferation responses of autistic and normal subjects to a set 
of peptide epitopes derived from pathogens suspected to cause the disease. 
HLA DR molecule-mediated autoimmunity may be involved in some cases of 
autism. For this reason, another model of autism is based on understanding of the 
autoimmune disorder rheumatoid arthritis (RA) and the roles played by specific HLA DR 
alleles. HLA DR molecules are T cell surface proteins involved in antigen presentation 
(Geha et al., 1994; Auger et al., 1996). In both RA and autism, individuals who possess 
either the HLA DR4 or DRl allele are susceptible to the diseases (Albani et al., 1992a; 
Warren et al., 1992; Daniels et al., 1995). DR proteins contain a set of allele-specific 
sequences known as hypervariable regions that have key roles in antigen binding and 
presentation, with the third hypervariable region (HVR-3) exerting a predominant effect 
(Geha et al., 1994). In RA, it is postulated that pathogens that display antigens with 
regions similar to the HVR-3 induce immune tolerance (Salvat et al., 1994). It is well 
noted that the E. coli dna J protein and EBV gpl 10 possessed a sequence identical to the 
core pentapeptide sequence (QKRAA) of the HVR-3 of HLA DR4 and DRl (Albani et 
al., 1992b). These E. coli dna J and EBV gpl 10 proteins appear to be important antigenic 
determinants associated with RA as a high titer of antibodies directed against them is 
found in the synovial fluid of RA patients (Takeuchi et al., 1990). Moreover, dna J and 
gp 110 act as potent inducers of T cell proliferation in both in vitro and in vivo assays 
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(Ikeda et al., 1996; Roudier et al., 1988, 1989). When DR4- or DR I-positive RA 
patients were tested for their T cell proliferative responses induced by peptides derived 
from the E. coli dna J protein and EBV gpl 10 that contained the QKRAA sequence, 
there was a significantly reduced response relative to RA patients and normal controls 
who expressed other DR alleles (Salvat et al., 1994). Based on these results, Salvat and 
his coworkers proposed that some cases of RA may be caused by infections with EBV or 
E. coli that are ineffectively cleared in HLA DR4- or ORI-positive individuals (Salvat et
al., 1994). Given the parallel between possession of HLA DR4 and ORI and 
susceptibility to RA and autism, we explored the possibility that DR4- or ORI-positive 
autistic individuals would show a reduced T cell proliferative response to dna J and 
gp 110 peptides that contain the QKRAA sequence. This communication reports the 
results of tests of both models of autism. 
MATERIALS AND METHODS 
Synthesis of T-Cell-Epitope-Derived 
Peptides 
Ten peptides that represent the major T cell epitopes of pathogens suspected in 
the etiology of autism were synthesized and purified by high performance liquid 
chromatograph at the Utah State University Biotechnology Center. Table 4.1 lists the 
amino acid sequences of these peptides. 
Subjects Studied 
The sex, age, and HLA DR types of the 24 autistic and 18 normal subjects 
Table 4.1 
Peptides Used in the T Cell Proliferation Assay 
Peptidea
Rubella capsid (9-29) 
Rubella El (262-283) 
Rubella E2 (51-75) 
HSV gC-1 (128-140) 
HSV gD-1 (5-23) 
CMV gB ( 618-628) 
Influenza M (58-66} 
Tetanus toxin (947-968 ) 
EBV gp 110 (803-818) 
E. coli dna J (56-75)
Sequence 
MEDLQKALEAQSRALRAELAA 
DPLLRTAPGPGEVWTPVIGSQ 
YRNASDVLPGHWLQEEWGCYN 
NRRDPLARYGSRC 
ADASLKMADPNRFRGKDLP 
FIAGNSAYEYV 
GILGFVFTL 
FNNFTVSFWLRVPKVSASHLEG 
EQNQEOKRAAbQRAAGC 
VLTDSQKRAAbYDQYGHAAF 
�umbers in parantheses indicate the amino acid position in the proteins 
bThe underlined sequences indicate the amino acid sequence shared with 
the HVR-3 region of HLA types DR4 and DRl. 
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included in this study are shown in Table 4.2. The diagnosis of autism was 
accomplished by psychiatrists according to criteria for autism of the American 
Psychiatric Association ( 1994 ). At the time of blood collection, there was no record that 
any autistic or normal subject received medications, had concurrent medical conditions 
that might affect the results of the study, or showed signs of infection or allergy. The 
studies were approved by the Utah State University Human Subject Review Board and 
written consent from study subjects or their parents was obtained. 
T Cell Proliferation Assay 
Peripheral blood mononuclear cells (PBMC) from fresh venous blood of each 
subject were isolated by histopaque density centrifugation. In outline, the T cell 
proliferation assay was based on previously published methods (Chain et al., 1987; Orlik 
and Spiltter, 1996) that were optimized in this laboratory (see Appendix B). These final 
conditions were used for all peptides in this study. For the assay, 5 x 106 PBMC freshly 
isolated from the same subject were placed in triplicate wells of 96-well flat-bottomed 
microculture plates (Cell Walls™, Corning, New York) and incubated at 37°C in a 
humidified 5% CO2 atmosphere. Peptides at a final concentration of 1 µM were added 
(see Appendix B). Triplicate negative controls without peptide addition were included in 
all experiments. One day later, recombinant interleukin type 2 (IL-2) was added to a final 
concentration of 30 international units/ml (Chiron, Emeryville, CA) (see Appendix B). 
Five days after starting the assay, 2 µI of 3H-thymidine (1 µCi; Moravek Biochemicals. 
Inc., Brea, CA) was added to each well. The cells were incubated 3 hours, then 
transferred by vacuum filtration to a membrane using a cell transfer device (Micromate-
Table 4.2 
Sex, Age and HLA DR Types of the Study Subjects 
Autistic Sex Age HLADR Normal Sex Age HLADR 
#1 M 3 7, 7 #1 M 3 7, 7 
#2 M 4 1, 13 #2 F 4 4, 7 
#3 M 5 7, 15 #3 M 5 11, 13 
#4 F 6 3, 3 #4 M 8 7, 7 
#5 M 6 1, 13 #5 M 8 1, 3 
#6 M 6 3, 7 #6 M 8 7, 11 
#7 M 9 4, 16 #7 F 9 13, 15 
#8 F 10 7, 13 #8 M 10 3, IO 
#9 M IO 7, 13 #9 M 14 11, 14 
#IO M 11 I, 15 #10 M 15 11, 13 
#11 M 11 7, 7 #11 M 15 4,8 
#12 M 12 I, 8 #12 F 16 4, 7 
#13 F 13 4,4 #13 M 16 13, 15 
#14 F 14 3,4 #14 M 16 11, 13 
#15 M 16 4, 15 #15 M 18 3, 13 
#16 F 16 1, 4 #16 M 18 1, 13 
#17 M 17 1, 7 #17 M 29 13, 15 
#18 M 19 4, 15 #18 M 41 1, 3 
#19 M 20 4, 7 
#20 M 23 4,4 
#21 M 25 1, 7 
#22 M 26 4, 15 
#23 M 27 1, 7 
#24 M 39 4, 15 
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196, Packard Instrument Inc., Dower Grove, IL). Unincorporated 3H-thymidine was 
removed by washing cells on the membrane and the incorporated counts were determined 
using a P-counter (Matrix™-96, Packard Instrument Inc., Dower Grove, IL). The average 
counts per minute (cpm) for triplicate wells analyzed for each condition (10 peptides and 
no peptide control) was calculated. A stimulation index (SI) for each peptide was 
calculated as the ratio of the average cpm incorporated in the presence of peptide over the 
average cpm of the no-peptide control in the same individual. 
Statistical Analysis 
The SI values were grouped into categories of positive response (SI > 1. 95), no 
response (1.95 �SI� 0.5), and negative response (SI< 0.5). The cutoffs of SI> 1.95 and 
SI < 0.5 are according to Schrier et al. ( 1995). x2analysis was performed to examine the 
significance of differences between the autistic and normal groups. The results were also 
analyzed on the basis of absolute cpm incorporated in the T cell proliferation assay. In 
this case, Student's t test was used. 
RESULTS 
Response to T-Ce/1 Epitopes of Pathogens 
Implicated in Autism 
PBMC obtained from a group of 24 autistic and 18 normal controls were 
challenged with 8 synthetic T cell epitopes of 5 pathogens (rubella virus, HSV-1, CMV, 
influenza A virus, and Clostridium tetani) that were implicated as potential causative 
factors in autism (Deykin and Macmahon, 1979). The proteins used to derive the 
synthetic T cell epitopes were the rubella virus caspid (C), envelop (E 1 ), and envelop 
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(E2) (McCarthy et al., 1993), HSV-1 glycoprotein C-1 (gC-1) and glycoprotein D-1 
(gD-1) (Jayaraman et al., 1993), CMV glycoprotein B (gB) (Mayer et al., 1996), the 
influenza A virus matrix (M) protein (Mayer et al., 1996), and the Clostridium tetani 
toxin (V almori et al., 1994 ), whose antigenecities are well demonstrated. 
The T cell proliferation induced by each peptide in each subject was expressed as 
SI, the ratio of 3H-thymidine incorporated by PBMC exposed to peptide relative to the
3H-thymidine incorporated by control cells not exposed to peptide. SI values ranged
widely for each peptide in both autistic and normal subjects. To facilitate comparisons 
between the autistic and normal groups, the method of Schrier et al. (1995) was followed 
in which SI values are classified into one of three categories: a positive response to the 
peptide (SI> 1.95), no response to the peptide (1.95 �SI� 0.5), and a negative response 
to the peptide (SI < 0.5). This simplification of results allowed testing of ranked T cell 
proliferative response by x2 analysis. 
The analysis of results for all eight peptides in autistic and normal subjects 
indicated that there was no reduction in T cell proliferation induced by any peptide in the 
autistic group (Table 4.3). The only difference between the autistic and normal groups 
was an increased response to the influenza A virus M protein in the autistic group (Table 
4.3) 
The results of peptide challenge to PBMC of autistic and normal subjects were 
also analyzed by comparing the mean cpm of the 3H-thymidine incorporated both in the
presence or absence of added peptides in the autistic and normal groups. As shown in 
Table 4.4, for all peptides the PBMC of autistic subjects incorporate less 3H-thymidine
than the equivalent number of PBMC of normal subjects under identical assay conditions. 
Peptide 
Rubella capsid (9-29) 
Rubella El (262-283) 
Rubella E2 (51-75) 
HSV gC-1 (128-140) 
HSV gD-1 (5-23) 
CMV gB (618-628) 
Influenza A virus M (58-66) 
Tetanus toxin (947-968) 
aStimulation index. 
Table 4.3 
Ranked T Cell Proliferation Response to Eight T Cell Epitopes 
Autistic Subjects (n = 24 ) 
Sia > 1.98 1.95 2: Sia 2: 0.5 Sia < 0.5 
6 13 5 
4 16 4 
3 17 4 
7 14 3 
3 18 3 
6 15 3 
5 13 6 
6 14 4 
Normal Subjects (n = 18) 
Sia > 1.98 1.95 2: Sia 2: 0.5 Sia < 0.5 
4 12 2 
3 13 2 
3 12 3 
3 13 2 
0 16 2 
3 13 2 
0 16 2 
3 11 4 
2 
X 
0.89 
0.27 
0.15 
1.00 
2.51 
0.50 
6.59 
0.51 
p value 
p > 0.05 
p > 0.05 
p > 0.05 
p > 0.05 
p > 0.05 
p > 0.05 
p < 0.05 
p > 0.05 
'° 
0 
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The difference between groups was significant according to Student's t test for all 
rubella- and HSY-derived peptides. The average 3H-thymidine incorporated by PBMC 
not exposed to peptide in the autistic and normal groups was actually higher than that 
observed following treatment with most peptides. This does not indicate that no 
individuals showed a positive response to peptide exposure, only that on average neither 
the autistic nor the normal group showed stimulation by peptides. This is consistent with 
the analysis of this data set by SI values, which shows that roughly equal numbers of 
individuals of each group respond positively or negatively to any peptide (Table 4.4). 
Stimulation with the mitogen, phytohemagglutinin (PHA), was used as a positive 
control to test the responsiveness of T cells in the PBMC preparations. For both the 
control and autistic groups, PHA induced a strong response over background levels 
observed in PBMC without any addition of mitogen (Table 4.4). As previously reported 
(Stubbs et al., 1977; Warren eta/., 1986), the level of 3H-thymidine incorporation in 
PHA-treated cells was lower in the autistic group relative to normal controls (Table 4.4). 
However, in contrast to these earlier reports, this difference was not statistically 
significant. 
Responses to Peptides with Sequences 
Similar to HLA DR4 or DRJ 
T cell proliferation was examined in response to peptides of the E. coli dna J and 
EBV glycoprotein (gp)l 10 protiens which contain the pentapeptide sequence QKRAA 
that is present in the HVR-3 of HLA OR4 or ORI. The average SI value of the OR4- or 
ORI-positive autistic subjects was compared with the SI value of three different groups: 
OR4- or ORI-negative autistic individuals (n = 7), OR4- or DRI-postitive normal 
92 
Table 4.4 
3H-Thymidine Incorporation after Exposure to 10 Peptides
in Normal and Autistic Subjects 
Autistic (n = 24) Normal (n = 18) Student's t Test 
Peptide µ± soa µ±SDa p valueb
Rubella capsid (9-29) 303 ± 334 1109 ± 1553 0.041 
Rubella El (262-283) 253 ± 265 801 ± 832 0.011 
Rubella E2 (51-75) 258 ± 264 806 ± 1111 0.049 
HSV gC-1 (128-140) 297 ± 278 957 ± 1272 0.040 
HSV gD-1 (5-23) 237 ± 268 644 ± 725 0.030 
CMV gB ( 618-628) 479 ± 965 938 ± 1154 0.149 
Influenza A virus M (58-66) 261 ± 301 1009 ± 1753 0.086 
Tetanus toxin (947-968) 354 ± 424 901 ± 1408 0.107 
PHA 3238 ± 3669 4997 ± 5971 0.228 
Background 405 ± 706 1054 ± 1283 0.054 
aMean ± standard deviation. 
bThe difference between the autistic and normal subjects was determined by Student's t 
test. 
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individuals (n = 6), and DR4- or ORI-negative normal individuals (n = 12). There was 
no significant difference in the average SI values in any comparison (Table 4.5). 
The ages of autistic subjects used in this study varied widely (3-39 years). Since 
age is known to be a factor in the immune response, we investigated whether age played 
a role in T cell responsiveness to peptides in the current study. Autistic subjects were 
grouped into categories of prepubescent children and adults using a cutoff age of 14 
years. The SI values observed in response to peptide exposure in these age groups are 
shown (Table 4.6). There was no significant effect of age in response to peptide. 
DISCUSSION 
Two questions were examined in this study. The first was whether autistic 
individuals have a compromised T cell-mediated immune response to pathogens reported 
to be associated with the disease. The second was whether pathogens with T cell 
epitopes similar to the T cell-interacting HVR-3 of HLA DR4 or DRl were tolerated in 
autistic individuals. Both questions were tested by examining the T cell proliferation 
responses of autistic and normal subjects to a set of peptide epitopes derived from 
pathogens implicated in autism. 
Averaged as a group, T cells of autistic subjects did not show a reduced 
proliferative response to peptides derived from rubella virus, HSV-1, CMV, influenza A 
virus, and Clostridium tetani. The only difference was an enhanced response to the 
influenza A virus M protein in autistic subjects. Therefore, these results do not provide 
support for the idea that a lower immune response to infections or immunization against 
common viruses plays a significant role in the disease. However, in coming to this 
Table 4.5 
Proliferation Response to EBV gpl 10 and E. coli. dna J Peptides8
Autistic Subjects with Autistic Subjects without Normal Subjects with Normal Subjects without 
DR4 or DRl (n = 17) DR4 or DRl (n = 7) DR4 or DRl (n = 6) DR4 or DRI (n = 12) 
Peptide Sib (µ± SDC) Sib (µ± SDC) Sib (µ± SDC) Sib (µ± SDC) 
EBV gpllO 1.10 ± 0.73 1.23 ± 1.16 1.75 ± 2.02 1.19 ± 0.65 
(803-818) 
E.coli dna J 1.79 ± 1.06 1.35 ± 1.55 2.90 ± 3.46 1.22 ± 0.66 
(56-75)
8Student's t test indicated no significant difference in SI between the DR4 or DRl positive autistic individuals compared to 
all other groups. 
bStimulation index. 
cMean ± standard deviation. 
\,0 
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Table 4.6 
Proliferation Response to 10 Peptides in 
Two Age Groups of Autistic Subjects8 
Age< 14 
(n = 13) 
Peptide Sib (µ± SDC) 
Rubella capsid (9-29) 1.30 ± 1.05 
Rubella El (262-283) 1.07 ± 0.74 
Rubella E2 (51-75) 1.12±0.68 
HSV gC-1 (128-140) 1.58 ± 1.38 
HSV gD-1 (5-23) 1.11 ± 0.95 
CMV gB (618-628) 1.92 ± 1.47 
Influenza A virus M (58-66) 1.21±0.93 
Tetanus toxin (947-968) 1.33 ± 0.99 
EBV gpl 10 (803-818) 1.11 ±0.91 
E. coli dna J (56-75) 1.39±1.11 
Age� 14 
(n = 11) 
Sib (µ± SOC) 
1.82 ± 1.28 
1.44 ± 0.70 
1.51 ± 0.76 
1.44 ± 0.65 
1.27 ± 0.85 
1.13 ± 0.40 
1.16±0.73 
1.79 ± 1.42 
0.96 ± 0.54 
1.71 ± 0.95 
8Student's t test indicated that there were no significant differences between 
age groups in response to any peptide. 
bStimulation index. 
cMean ± standard deviation. 
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conclusion, it is important to realize that widely varying individual responses were 
seen in each group. It remains possible, as suggested by epidemiological studies, that 
some cases of autism are caused by infectious agents. If these cases occur at low 
frequency, the method of comparison between groups that was used here would fail to 
detect them. 
The second hypothesis examined in this work was the possibility that autism may 
be induced by pathogens that possess protein antigens that share sequences with the HLA 
DR4 or DRl . These particular DR types are expressed at much higher frequencies in 
autistic subjects than in the general population (Daniels et al., 1995; Warren et al., 1992). 
We measured the ability of the HVR-3-like peptide epitopes (dna J from E. coli and 
gpl 10 for EBV) to induce T cell proliferation in autistic and normal subjects. Both E. coli 
dna J and EBV gp 110 are significant antigens of each pathogen and dna J antibodies and 
activated T cell clones have been reported in the synovial fluid of RA patients (Winfield, 
1989; Albani et al., 1992a; Ikeda et al., 1996). Our results failed to provide support for 
the hypothesis that DR4- or DRl-postitive autistic individuals are tolerant to the E. coli 
and EBV peptides that share sequences with the HVR-3 ofHLA DR4 or DRl. The same 
caveat holds in this study of the response to HLA DR4- and ORI-like peptides as for the 
investigation of the response to pathogen -derived peptides: a comparison of group 
averages will not detect a small number of cases of autism that result from immune 
tolerance of E. coli or EBV in DR4- or ORI -positive subjects. 
Although peptide-specific differences in T cell response between autistic and 
normal subjects were not detected in this investigation, a striking finding was the 
generally lowered T cell proliferation seen in autistic individuals. The analysis of 
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peptide-specific responses was made by comparisons of the SI. However, when the 
absolute amount of 3H-thymidine incorporated in the assay is compared, the PBMC of 
autistic individuals incorporated only about half the amount of 3H-thymidine with or 
without peptide than PBMC of normal subjects. This difference could be due to reduced 
T cell activity in autistic individuals as the same numbers of fresh PBMC (5 x 106) were 
assayed in all individuals. It is likely that reduced T cell function would adversely affect 
the immune capabilities of autistic subjects. A generally depressed immune response 
using various measures has been reported frequently in autism (Warren et al., 1987, 
1990, 1991; Y onk et al., 1990). This global depression in immune responsiveness, 
whatever its cause, may play a more important role in autism than reduced 
responsiveness to any one particular pathogen. 
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CHAPTERS 
SUMMARY 
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Immune system abnormalities and infection have long been suspected as factors 
that trigger autism (Rimland, 1964; Warren et al., 1986). However, before the work 
reported here, it was unknown whether T or B cell abnormalities played a dominant role 
in the disease, if there was expansion of specific T cell clones, or if autistic individuals 
responded abnormally to any specific pathogens. The involvement of T or B cells in 
autism was explored in this work by examining the expression of cytokine markers of T 
or B cell immune responses. Later studies examined if T cell clone expansion occurs in 
autism by assessing the expression of all 24 major T cell receptor (TCR) V-P chain genes 
in autistic and normal individuals. Finally, the potential link between T cell-mediated 
autoimmunity, infectious agents, and autism was explored by examining T cell 
proliferation in response to antigens derived from a panel of pathogens. The results of the 
studies reported here provide new insights into this complex disease. 
My results demonstrating elevated levels of interleukin type 2 (IL-2) and 
interferon-y in autism suggest that T cells rather than B cells are involved in the disease. 
Since IL-2 and interferon-y are markers of CD4+ T cell activation, the elevated 
expression of these cytokines indicates that activated CD4+ T cells play a role in the 
disease. Activation of CD4+ T cells is also known as a Th 1 type immune response and 
activation of B cells is termed a Th2 response. The finding of a Th l immune response in 
autism is significant because treatment strategies for Thl and Th2 responses differ. 
Therapy for Thl responses involves administration of cytokines, such as IL-4, that are 
104 
elevated in Th2 type responses (Romagnani, 1995, 1996, 1997). This may be a 
productive avenue to explore for treatment of autism, a disease in which no effective 
treatments are available. 
The TCR V-P chain repertoire was found to be altered in autistic patients, and this 
finding provided the clear evidence for the expansion of specific T cell clones. Using 
competitive reverse transcription-polymerase chain reaction (RT-PCR), I quantified the 
abundance of mRNA of each of the 24 major TCR V-P chains in autistic and normal 
individuals. This is the first time a study of this scope has been performed in the 
investigation of autism. As a group, autistic individuals express significantly higher 
levels of V-P 13 and lower levels of V-P 19 and 22. These results suggest that there is 
biased expression of specific T-cell clones and support the hypothesis of altered T cell 
function in autism. 
The antigen-presenting human leukocyte antigen (HLA) DR4 or ORI allele 
occurs frequently in autistic individuals. I examined the possible association between 
these HLA DR molecules and T cell clone expansion by searching for an association 
between these alleles and the expression of specific TRC V-P chains. HLA DR4- or 
DR 1-postive autistic individuals (n = 7) showed significantly elevated V-P 13 expression 
compared to normal individuals (n = 5). This result highlights the role played by these 
HLA DR molecules in the disease. There was no difference in V-P 19 and 22 expression 
between the DR4- or ORI-positive normal and autistic individuals. It appears that the 
expansion ofV-P 13-expressing T cell clones is favored by HLA DR4 or DRl ,  whereas 
deletion ofV-P 19 and 22 is independent of the HLA DR4 or ORI alleles. 
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If the expansion of V-13 13 is a general feature of autism, it may open a path 
for the treatment of the disease. V-13 13-expressing clones could be blocked through 
immune therapy to potentially ameliorate disease symptoms. Moreover, the expansion of 
V-13 13-expressing clones may serve as the first physiologically based diagnostic tool for
autism. 
The final portion of this dissertation explored the possibility that infections by 
certain agents may contribute to autism. Epidemiological studies have linked infections 
and autism (Deykin and Macmahon, 1979). The hypothesis that autistic individuals 
demonstrate an altered immune response to some infectious agents was examined by 
observing T cell proliferation in response to a panel of T cell epitopes. These synthetic 
peptide epitopes represented the major T cell epitopes of a list of pathogens implicated in 
the development of autism. Comparison of a group of 24 autistic and 18 normal subjects 
did not show a reduced T cell proliferative response in autistic patients to peptides 
derived from rubella virus, herpes simplex virus type 1 (HSV -1 ), cytomegalovirus 
(CMV), or tetanus. The only difference between groups that was detected was an 
enhanced response to the influenza A virus epitope (matrix (M) protein) in autistic 
subjects. Therefore, these results do not provide support for the idea that a lower immune 
response to infectious agents plays a significant role in the disease. It is important to 
realize, however, that comparisons were made between the group averages of autistic and 
normal ·subjects and that widely varying individual responses were seen in each group. It 
remains possible that some cases of autism are caused by infectious agents, as suggested 
by previous epidemiological studies. However, if these cases occur at low frequency, 
they would be undetected because they would not significantly affect the average group 
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response. If autism indeed is a multifactorial disease, teasing out any individual factor 
becomes difficult. 
One of the most striking findings in the immunogenetics of autism is the strong 
association of HLA DR4 or DRl with the disease. One postulate for this association is 
molecular mimicry between these antigen-presenting molecules and sequences found in 
some common pathogens. The Escherichia coli (E. coli) dna J protein and EBV gp 110 
are both significant antigens of these infectious agents (Roudier et al., 1988, 1989; Ikeda 
et al., 1996) and both possess an amino acid sequence that is nearly identical to a critical 
region of the DR4 or DRl gene products. 
Results reported in Chapter 4 of this dissertation failed to provide support for the 
hypothesis of molecular mimicry between HLA DR4 or DRl and E. coli dna J or EBV 
gpl 10. No relationship between possession of the HLA DR4 or DRI and the ability to 
respond to the E. coli and EBY epitopes was detected in any group examined. There were 
no differences in response to these peptides related to the DR4 or ORI allele. The same 
caveat holds in this study of the response to HLA DR4- and DRl-like peptides as for the 
investigation of the response to pathogen-derived peptides: a comparison of group 
averages will fail to detect a small number of cases of autism that result from immune 
tolerance of E. coli or EBY in DR4- or DRl-positive subjects. 
What do the results of this dissertation say about the etiology of autism? First, it is 
essential to realize that autism is likely to be a multifactorial disorder; no one cause is 
responsible for autism in all affected individuals. Two leading postulates for causative 
factors in autism are autoimmunity and infectious agents. My results provide support for 
a role of autoimmunity in the disease, but failed to find evidence for the influence of 
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specific pathogens. Activation of CD4+ T cells is a hallmark of T cell-mediated 
autoimmunity. Therefore, my observation that many autistic individuals have activated 
CD4+ T cells suggests the involvement of autoimmunity in the disease. Significantly, 
there appears to be an expansion of specific T cell clones in autistic individuals. This was 
demonstrated by the augmented expression of one V -� 13 mRNA. A similar situation 
occurs in the autoimmune diseases rheumatoid arthritis and multiple sclerosis where 
mono- or oligoclonal T cell expansion is observed (Urban et al., 1988; Jenkins et al., 
1993). There are many models that can incorporate these observations into the etiology of 
autism, but at this stage, all are speculative. The proposal I favor merges the results of 
this dissertation with the observation that in animal models activated T cell clones in 
peripheral blood can cross the blood-brain barrier (Wekerle et al., 1986). I propose that 
activated peripheral blood T cells cross the blood-brain barrier where they recognize CNS 
components as antigens. These activated T cells are predicted to release IL-2 and other 
cytokines that recruit inflammatory cells, macrophages, effector T cells, and antigen 
presenting cells. These cells would produce CNS tissue damage. In combination with 
autoimmune attack on the CNS, this would create CNS lesions that cause autism. In 
support of these ideas, in animal models of multiple sclerosis, specific T cell clones 
activated in peripheral blood are also found within CNS tissues. 
Obvious questions that stem from this model is whether T cell infiltration can be 
demonstrated in autism and, if so, whether T cell infiltration is involved only in autism or 
plays a more general role in other neurological disorders. An animal model of autism, 
which is currently not available, would greatly accelerate research into these and related 
questions. 
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Both Todd (1986) and Warren et al. (1987) proposed immune tolerance as an 
alternative mechanism to autoimmunity in the etiology of autism. Autistic individuals 
often exhibit decreased immune functions of T cells (Warren et al., 1986), B cells 
(Warren et al., 1986), natural killer cells (Warren et al., 1987), immunoglobulin A 
(Warren et al., 1997), and complement C4B (Warren et al., 1995). My results did not 
indicate a reduced T cell proliferation in response to any single peptide in autistic 
individuals, but did show that there was a generally lowered T cell proliferation in 
autistic subjects whether untreated or challenged with peptide. It is likely that reduced T 
cell function would adversely affect the immune competence of autistic subjects. This 
widespread reduction in immune responsiveness, whatever its cause, may play a more 
important role in autism than immune tolerance to specific pathogens. Given the 
proposed mulitfactorial nature of autism, autoimmunity and a generally depressed 
immune system function are not mutually exclusive possibilities for the development of 
the disease. 
The results of this dissertation open more questions than they answer and a 
comprehensive understanding of the disease remains a distant hope. Some of my results, 
however, especially the finding of specific T cell clone expansion, may pave the way to 
diagnosis and, more optimistically, therapy for the disease. 
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APPENDIX A 
PHA STIMULATION OF CRYOPRESERVED PBMC: 
A METHOD TO AMPLIFY T CELLS 
ABSTRACT 
An important technical issue in the analysis of T cell populations involved in 
human T cell-mediated diseases is the limited number of these cells in affected tissues 
(Fujihashi et al., 1996; Jenkins et al., 1993). Amplification of primary T cell populations 
by mitogen treatment is a commonly used approach to circumvent this problem. Often, 
the primary populations of T cells are cryopreserved prior to mitogen stimulation. 
However, there are conflicting reports regarding whether amplification of primary T cell 
populations skews the distribution of T cell subtypes. In this communication, the affect of 
phytohemagglutinin (PHA) stimulation of freshly isolated or cryopreserved peripheral 
blood mononuclear cells (PBMC) on the distribution of T cell subtypes was examined. T 
cell receptor (TCR) V -P chain expression was used to assess the distribution of T cell 
subtypes. The expression of all the 24 major TCR V-P chains was analyzed by 
competitive reverse transcription-based polymerase chain reaction (RT-PCR) in the 
PBMC of three subjects. The results show that PHA stimulation of fresh or cryopreserved 
PBMC did not significantly alter the TCR V-P chain repertoire of the cells. 
INTRODUCTION 
Analysis of TCR repertoires is used to identify T cell clones that are activated 
during infection and disease (Ohga et al., 1999; Than et al., 1999). The expansion of a 
single or limited number of T cell clones occurs in many human autoimmune disorders 
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(Wucherpfennig et al., 1995; Abe et al., 1993; Moller et al., 1988). The identification 
of these clones offers the hope of therapy based on deletion of the specific activated 
clones (Urban et al., 1988; V andenbark et al., 1989). The variable region of the J3 chain 
(V-J3) is the most commonly examined molecular marker ofT cell identity (Arche-Orbea 
et al., 1988; Keystone et al., 1995; Posnett et al., 1990). The small number of T cells that 
can be recovered from either affected tissues or the peripheral blood is a limiting factor in 
the study of autoimmune and other T cell-based disorders. One approach to circumvent 
restricted T cell number is to amplify the T cell population by treatment with a mitogen 
such as PHA. A concern with such an approach is that particular clones may be 
selectively amplified or lost, creating an altered population that poorly mirrors the 
original clonal diversity. There are conflicting reports as to whether this is a real or 
hypothetical issue. Using flow cytometry and a limited list of monoclonal antibodies 
available for TCR V-J3 chain, Davey and Munkirs (1993) found that treatment of PBMC 
with the mitogen ConA skewed V-J3 chain expression compared to the starting population 
of cells. However, when using PHA to stimulate growth, Jason et al. (1996) found that 
there was an unbiased representation of clones in the expanded population. 
The studies reported in Chapter III of this dissertation required a significant 
number of T cells from a large group of autistic and control individuals. This necessitated 
some method of increasing T cell number. The studies presented in this appendix 
examined if either of two methods of T cell expansion produced an unbiased V-J3 
repertoire identical to that of the initial T cells. The expression of the 24 major V-J3 
chains was studied using the sensitive technique of competitive RT-PCR. The results 
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show that PHA stimulation of either fresh or cryopreserved PBMC did not alter the 
repertoire of V-P chain expression. These results justify the use of PHA-stimulated fresh 
or cryopreserved cells in the studies of this dissertation. 
MATERIALS AND METHODS 
Isolation of Total RNA 
Blood was drawn from three volunteers into vacutainer tubes and PBMC were 
isolated by histopaqua (Sigma, St. Louis, MO) density centrifugation. The PBMC were 
divided and placed into three treatment groups: I) fresh PBMC (5 x 106); 2) fresh PBMC 
(5 x 105) cultured with 10 µg/ml PHA (Gibco BRL, Grand Island, N.Y.) for five days;
and 3) PBMC (5 x I 05) cryopreserved at -70°C for IO days, thawed, then stimulated with 
PHA as above. Total RNA was isolated using Trizol (Gibco, Gaitherburg, MD) from 5 x 
I 06 primary or PHA-stimulated PBMC, and then dissolved in 30 µl of sterile H20. Total
RNA concentration was measured by absorbance at 260 nm. 
cDNA Synthesis and RT-PCR 
To synthesize cDNA, 2 µg of total RNA was reverse-transcribed in a 20-µl 
reaction mixture at 37°C for two hours according to the manufacturer's instructions 
(Promega, Madison, WI). The resulting cDNA was divided equally into 24 tubes, each 
containing a 5' TCR V-P-specific sense primer, a common 3' TCR V-P C antisense 
primer, I 00 femtomoles of a reference cDNAs (also called competitor), and the other 
PCR components described in Chapter III of this dissertation. PCR was performed in a 15 
µl reaction volume using an initial 5 minutes of denaturation at 94 °C followed by 30 
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cycles of the profile: 1 minute at 94 °C, 1 minute at 58 °C and 1 minute at 72 °C. TCR 
V-13 21 was used to optimize competitive RT-PCR, and these conditions were applied to
all 24 V-13 chains. PCR products were analyzed by electrophoresis through 2% agarose 
gels. 
Analysis of PCR Products 
Analysis of PCR products was performed according to Spinella and Robertson 
(1994). Briefly, a photograph of the agarose gel was converted to a digital image. The 
image was analyzed using the digital processing program from Biosoft Inc. (Ferguson, 
MO). The intensities of endogenous cDNA products were normalized relative to that of 
the most intense band. A similar normalization was performed for the reference cDNA 
amplification products, each 86-bp larger than the corresponding endogenous bands. The 
ratio between the normalized values of each endogenous band relative to its 
corresponding reference band was calculated and termed the relative expression index 
(REI). 
Statistical Analysis 
The V-13 repertoires of each treatment regimen were arranged in descending order 
of REI values. For each treatment in each individual, Spearman's rank test was used to 
calculate an rs value [rs= 1- (6 x (Id?)/(n3 -n))], where di represents the rank difference 
between the repertoires of fresh PBMC vs the repertoires of any other two treatments, 
and n is the sample size. Then, Spearman's t test was employed according to Harnett 
(1982) to test the significance of differences between treatments. In Spearman's t test, t= 
rs x [(n-2)/(1-r/)]
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, while r5 represents the rank sum and n is the sameple size. The t 
value was used to assess the significance of differences (p value). 
RESULTS AND DISCUSSION 
Analysis of V-/3 Chain Repertoires by 
Competitive RT-PCR 
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V-P chain expression was analyzed by competitive RT-PCR. This technique has
the advantages of sensitivity relative to Southern analysis and flow-cytometry, two 
methods traditionally employed for these studies. Optimizations of R T-PCR were 
performed using V-P-21 as a representative V-P chain. Two µg of total RNA from 
PBMC were used to synthesize cDNA. Aliquots (2 µl) of the cDNA were co-amplified 
with varying amounts of reference cDNA. Reference cDNA is a V-P-21 gene modified 
by insertion of an 86-bp sequence. This distinguishes reference and endogenous cDNA 
amplification products. Amplification was carried out for 30 cycles. The amount of 
starting endogenous cDNA is determined in one of two ways. In an experiment, such the 
one shown in Figure 6.1, the lane that demonstrates equal intensity of the reference and 
endogenous cDNA bands gives the amount of starting endogenous cDNA as this equals 
the known starting amount of reference cDNA. In Figure 6.1, this is lane 5 and the 
amount of endogenous cDNA therefore is 25 femtomoles. In large-scale assays involving 
many samples, such as those used to analyze the 24 major V -P chains from dozens of 
individuals, optimization for all samples is impractical. In this case, one talces advantage 
of the linear relationship between the log ratio of reference/endogenous band intensity to 
the log of reference cDNA molecules. This relationship for the PCR shown in panel A of 
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9 M 
Fig. 6.1. Competitive RT-PCR analysis ofTCR V-P 21 expression. Panel A. Two µl 
of the endogenous cDNA were co-amplified with 2 µl of reference cDNA prepared as a 
series of I :2 dilutions with a starting amount of I 00 femtomole ( I fmole = 10- 15 moles) 
(lane 1-8). Lane 9 contained 2 µI of endogenous cDNA only. M: DNA size marker. Panel 
B. Quantitative analysis of the data plotted in panel A.
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Figure 6.1 is demonstrated in panel B of the same Figure. In experiments, such as 
those presented in Chapters II and III, the log10-transformed ratio of reference to 
endogenous bands is determined and the amount of endogenous cDNA is derived from 
the x intercept of this ratio. 
Having established conditions for the amplification of TCR V-P-21, the assay was 
extended to all 24 V-P clones. Two µl of endogenous cDNA and IO femtomoles of 
reference cDNA were aliquoted into 24 tubes and amplified by PCR under identical 
conditions. Figure 6.2 shows a gel displaying a typical PCR using cDNA derived from 
fresh PBMC of a single donor. In each lane, two DNA bands were generated, the smaller 
one from endogenous cDNA and the larger one from the reference cDNA. As expected, 
the products from reference cDNAs were 86-bp larger than their corresponding 
endogenous products. 
Analysis of the relative levels of expression of each V-P chain was performed 
using software from Biosoft, Inc. The analysis compares the densities of the endogenous 
and reference cDNA products in each lane and normalizes these relative to the highest 
endogenous/reference cDNA ratio observed in an individual. These normalized ratios, 
termed the relative expression index (REI), assess the relative expression level of each V­
P chain in an individual. Analysis of the PCR shown in Figure 6.2 indicated that V-P 5, 8, 
and 13 were the predominant V-P chains expressed in this individual (Figure 6.3). 
Comparison of the TCR V-/3 Repertoire 
from Fresh and Amplified PBMC 
V-P chain expression was compared in fresh PBMC, fresh PBMC directly
12l) 
Lane , 2, � s 6 1s910111211,11J141s16111s1920 21222324 
Fig. 6.2. RT-PCR of 24 TCR V-13 mRNAs expressed in PBMC of donor l .  The total 
RNA was extracted from peripheral blood mononuclear cells and cDNA was synthesized 
in vitro using reverse transcriptase at 3 7°C overnight. The resulting cDNA was used as 
the template to set up PCR. PCR Then, the PCR products were run on 2% DNA agarose 
gel for I hour, stained by ethidium bromide and visualized under UV light. (Lanes l-12 
represent TCR V-13 l -12; Lane M representsl-kb DNA size marker and 500-bp DNA size 
band is the major marker to judge the RT-PCR products; Lanes 13-24 represent RT-PCR 
products from TCR V-13 13-24.) All RT-PCR products were identified to have the correct 
sizes and the endogenous products were confirmed to be constantly 86-bp smaller than 
the corresponding reference cDNA products. 
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stimulated by PHA, and cryopreserved PBMC stimulated by PHA after thawing. 
Figure 6.3 shows the REis of 24 V-P chains from fresh or PHA-stimulated PBMC taken 
from the same individual analyzed in Figure 6.2. This analysis shows that V-P 2, 5, 8, 
and 13 were the predominant clones in all three PBMC preparations. Visual inspection of 
the results indicates that PHA treatment alone or coupled with cryopreservation did not 
alter the V-13 repertoire. PBMC preparations from two additional donors were treated 
under the same three conditions (Figures 6.4 and 6.5). Once again, visual inspection 
showed that the expression repertoire was not altered by PHA treatment alone or PHA 
treatment following recovery from cryopreservation. A different pattern of V -P chain 
expression was observed in each of the three normal subjects (Figures 6.3, 6.4 and 6.5). 
A more rigorous analysis of the data was made using Spearman's rank test. This 
test measures the significance of differences in rank of V-P chain expression under the 
three experimental conditions. A p value of less than 0.01, which indicates no significant 
difference, was found in each subject for comparisons between V-P expressions in fresh 
PBMC relative to PBMC stimulated by PHA under either treatment regimen (see Table 
6.1). 
These findings of the study are significant because they show that long-term 
storage of T cell populations and their subsequent amplification is possible without 
skewing the original composition of T cell subtypes. 
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Table 6.1 
Spearman's Rank Test ofTCR V-P Expression in Three Donors 
Fresh vs PHA-Stimulated 
Donor 
1 
2 
3 
fs
a
0.766 
0.813 
0.774 
tb pc
5.59 < 0.01 
6.56 <0.01 
5.73 <0.01 
8The rank sum values of Spearman's rank test. 
bt values of Spearman's rank test. 
cp value of Spearman's rank test. 
Fresh vs Cryopreserved 
fs
a
0.744 
0.849 
0.884 
tb pc
5.23 <0.01 
7.55 <0.01 
8.89 <0.01 
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ABSTRACT 
APPENDIXB 
OPTIMIZATION OF A PEPTIDE-MEDIATED 
T CELL PROLIFERATION ASSAY 
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Optimal conditions were established for T cell proliferation stimulated by 
synthetic peptide epitopes. The effect of varying the epitope concentration, the type and 
amount of cytokines, and the concentration of serum were examined. The optimized 
assay utilized peripheral blood mononuclear cells (PBMC) cultured with 10% fetal 
bovine serum, 30 international units (IU)/ml interleukin type 2 (IL-2), and 1 µM synthetic 
peptide. 
INTRODUCTION 
The T cell proliferation assay is an important experimental tool to assess the 
response ofT cells to antigens (DuPont et al., 1985; Rychlikova et al., 1971; De Graeff­
Meeder et al., 1991). Current applications of the assay often employ synthetic peptide­
mediated epitopes to stimulate T cell proliferation (Schrader et al., 1991 ). It is critical to 
establish optimal conditions for the assay, especially when using synthetic epitopes, 
which often are only weakly antigenic (Bromelow et al., 1997; Yang et al., 1995; 
Durinovic-Bello et al., 1996). The influence of peptide concentration, the type and 
amount of cytokines, and serum levels on the T cell proliferation assay were investigated 
(Bertram et al., 1997; Hao et al., 1986; and Lamers et al., 1992). 
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MATERIALS AND METHODS 
Synthetic Peptide Epitopes 
Ten peptides derived from known or predicted epitopes of pathogens potentially 
involved in autism were synthesized at the Utah State University Biotechnology Center. 
The peptides were purified by reverse-phase high performance liquid chromatography, 
and diluted in RPMI-1640 (RPMI Inc., Cellgro, VA). Their amino acid sequences are 
listed (see Table 4.1 of chapter IV). 
T Cell Proliferation Assay 
PBMC were isolated from fresh blood of normal healthy donors by histopaque 
(Sigma, St. Louis, MO) density centrifugation. PBMC were cultured in 96 well plates 
using RPMI-1640, fetal bovine serum (usually 10%), and synthetic epitopes. When 
recombinant cytokines were included, they were added 24 hours after beginning cell 
culture (Chain et al., 1987). Five days after adding synthetic peptide, 2 µl of 3H­
thymidine ( 1 µCi; Moravek Biochemicals. Inc., Brea, CA) was added to each well, cells 
were incubated for 3 hours, then transferred to a filter membrane (Packard Instrument 
Inc., Dower Grove, IL) using a cell harvesting device (Micromate-196, Packard 
Instrument Inc., Dower Grove, IL). The unincorporated 3H-thymidine was removed by 
vacuum filtration, and the counts associated with the cells determined using a direct P-ray 
counte� (Matrix ™-96, Packard Instrument Inc., Dower Grove, IL). Proliferation indices 
were expressed as the ratios of the average counts per minute ( cpm) from triplicate 
antigen-containing test wells to the average cpm of triplicate control wells without 
antigen. 
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RESULTS AND DISCUSSION 
Peptide Concentration 
The effect of 4 different synthetic peptides, rubella capsid, rubella E2, HSV-1 ge­
l and tetanus toxin on T cell proliferation was investigated in cells cultured without any 
added cytokines. Each peptide was added at 5 different concentrations that ranged 
between 1 x 10-3 µM - 10 µM. Typical peptide concentrations used in T cell proliferation 
assays range between 0.01 and 1 µM (Orlik et al., 1996; Mayer et al., 1996). The 
proliferation index at any peptide concentration never exceeded 1.6. Later studies (see 
below) demonstrated that a cytokine must be added to the cells to increase the 
proliferation index to more significant values. Nonetheless, the peptide dose-response 
relationships shown in Figure 7. I indicate that for most peptides a concentration of I µM 
was the most effective. Increasing the concentration to IO µM almost always was 
inhibitory. 
Cytokines 
Cytokines play essential roles in T cell proliferation (Chain et al., 1987). The 
effect of IL-2, interleukin type 3 (IL-3 ), interleukin type 4 (IL-4 ), interleukin type 6 (IL-
6), interleukin type 12 (IL-12), platelet-derived growth factor (PDGF) on T cell 
proliferation without added peptide was investigated. As shown in Figure 7.2, IL-2 was 
the most potent cytokine for T cell proliferation. For peptide-stimulated T cell 
proliferation, a cytokine concentration that stimulates cell growth roughly between 2- and 
10-fold is optimal. Increasing the proliferation index above these values produces a low
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Fig. 7.2. Effect of different cytokines on the T cell proliferation assay. 
signal-to-noise ratio associated with addition of peptide. For this reason, a 
concentration 30 IU/ml of IL-2 in the culture medium was chosen as the standard for 
assays of this dissertation. 
Interaction between Peptide and IL-2 
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The effect of IL-2 addition (30 IU/ml) on T cell proliferation assay increased the 
sensitivity of the assay, and the stimulation index derived from 10 synthetic peptide 
epitopes used in this dissertation is shown in Figure 7.3. There is some disagreement on 
what constitutes a significant level of enhanced proliferation, with most researchers 
placing the minimum value of the proliferation index at either 1.5 or 2.0. Applying a 
value of 2.0, Figure 7.3 indicates that the peptide of Epstein-Barr virus (EBY) gp 110 and 
tetanus toxin induced significant proliferation, but only when PBMC were cultured with 
IL-2. A significantly difference was found between with added IL-2 (30 JU/ml) and 
without added IL-2 by Student's t test (p < 0.01). 
Serum Concentration 
Published reports employing the T cell proliferation assays call for serum levels 
between 1-10% (Orlik et al., 1996). The effect of fetal bovine serum concentrations of 
1 % and 10% on T cell proliferation stimulated with 3 different peptides was examined 
and the results are shown in Figure 7.4. A 10% serum concentration was essential for the 
assay. 
The Optimized Assay 
Based on the results described above, the standard T cell proliferation assay 
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from different individuals. 
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employed in this thesis utilized PBMC cultured with l 0% serum, 30 IU/ml IL-2, and 
l µM synthetic peptide.
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